FLT3

Summary

FLT3 (fms related receptor tyrosine kinase 3, HGNC:3765) is a protein-coding gene on chromosome 13q12.2, encoding Receptor-type tyrosine-protein kinase FLT3 (P36888). Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. In precision oncology, FLT3 ITD confers sensitivity to Gilteritinib in Acute Myeloid Leukemia (CIViC Level A); 80 further curated variant–drug associations are listed below.

This gene encodes a class III receptor tyrosine kinase that regulates hematopoiesis. This receptor is activated by binding of the fms-related tyrosine kinase 3 ligand to the extracellular domain, which induces homodimer formation in the plasma membrane leading to autophosphorylation of the receptor. The activated receptor kinase subsequently phosphorylates and activates multiple cytoplasmic effector molecules in pathways involved in apoptosis, proliferation, and differentiation of hematopoietic cells in bone marrow. Mutations that result in the constitutive activation of this receptor result in acute myeloid leukemia and acute lymphoblastic leukemia.

Source: NCBI Gene 2322 — RefSeq curated summary.

At a glance

• Gene–disease (curated): leukemia, acute myeloid, susceptibility to (Limited, ClinGen)
• GWAS associations: 63 (top 1% of genes corpus-wide)
• Clinical variants (ClinVar): 247 total — 10 pathogenic, 4 likely-pathogenic
• GTEx eGene: eQTL in 33 tissues, sQTL in 1 (q < 0.05)
• Phenotypes (HPO): 5
• Drug target: yes — 39 curated mechanism-of-action drugs; 143 molecules with ChEMBL bioactivity (top 1% of genes corpus-wide)
• Approved drugs (ChEMBL mechanism of action): 8 — Fedratinib, Gilteritinib, Midostaurin, +5 more
• Precision-oncology evidence (CIViC): 81 curated variant–drug associations
• Cancer driver (intOGen): activating (oncogene-like) across 2 cancer types (inferred from mutation patterns)
• Constraint (gnomAD): pLI 1.00 (loss-of-function intolerant), LOEUF 0.47 (moderately constrained)
• Transcription factor: yes — 19 downstream targets (CollecTRI)
• MANE Select transcript: NM_004119
• Interaction hub: 2,904 STRING partners (top 3% of genes corpus-wide)

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3765
Approved symbol	FLT3
Name	fms related receptor tyrosine kinase 3
Location	13q12.2
Locus type	gene with protein product
Status	Approved
Aliases	STK1, FLK2, CD135
Ensembl gene	ENSG00000122025
Ensembl biotype	protein_coding
OMIM	136351
Entrez	2322

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 3 protein_coding, 2 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

MANE Select: ENST00000241453

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 3: 1

ENST00000241453, ENST00000380987, ENST00000469894, ENST00000864668, ENST00001004561, ENST00001131816

RefSeq mRNA: 1 — MANE Select: NM_004119 NM_004119

CCDS: CCDS31953

Canonical transcript exons

ENST00000241453 — 24 exons

Exon	Start	End
ENSE00000827401	28037185	28037288
ENSE00000827402	28035935	28036043
ENSE00000827403	28035495	28035673
ENSE00000827404	28034301	28034407
ENSE00000827405	28034082	28034214
ENSE00000827406	28033887	28033991
ENSE00000827407	28028178	28028288
ENSE00000827408	28027088	28027241
ENSE00000906608	28048275	28048443
ENSE00000906609	28049384	28049537
ENSE00000906610	28049635	28049774
ENSE00000906611	28050095	28050222
ENSE00000906612	28052545	28052674
ENSE00000906613	28057347	28057462
ENSE00000906614	28061867	28062069
ENSE00000906615	28070491	28070612
ENSE00001487116	28003274	28004174
ENSE00003513156	28014452	28014557
ENSE00003519436	28023350	28023477
ENSE00003552851	28015590	28015701
ENSE00003565636	28024861	28024943
ENSE00003598146	28018467	28018589
ENSE00003692016	28015157	28015256
ENSE00003896396	28100468	28100576

Expression profiles

Bgee: expression breadth ubiquitous, 166 present calls, max score 86.25.

FANTOM5 (CAGE): breadth broad, TPM avg 2.7806 / max 577.0111, expressed in 297 samples.

Highest expression (Bgee): male germ line stem cell (sensu Vertebrata) in testis, cerebellar hemisphere, cerebellar cortex, monocyte, mononuclear cell.

Genetic regulation across tissues (GTEx eQTL / sQTL)

FLT3 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 33 tissues and its splicing (sQTL) in 1 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 34 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Brain Cerebellum	eqtl	1.9e-71	+1.21	13:28027857:G:A
Brain Cerebellar Hemisphere	eqtl	4.6e-67	+1.21	13:28027514:T:C
Brain Cortex	eqtl	6.8e-51	+1.00	13:28027514:T:C
Brain Anterior cingulate cortex BA24	eqtl	2.6e-38	+0.94	13:28033573:G:C
Brain Frontal Cortex BA9	eqtl	2.1e-36	+1.00	13:28033573:G:C
Pancreas	eqtl	3.2e-25	-0.75	13:28086023:T:A
Skin Sun Exposed Lower leg	eqtl	1.0e-22	+0.39	13:28028119:C:T
Brain Hypothalamus	eqtl	1.1e-20	+0.69	13:28028467:T:C
Skin Not Sun Exposed Suprapubic	eqtl	1.8e-13	+0.34	13:28028119:C:T
Nerve Tibial	eqtl	5.4e-11	+0.33	13:28033573:G:C
Brain Putamen basal ganglia	eqtl	6.0e-09	+0.63	13:28031877:G:A
Brain Caudate basal ganglia	eqtl	1.3e-08	+0.64	13:28032042:T:A
Lung	eqtl	1.5e-08	+0.29	13:28018990:G:A
Brain Nucleus accumbens basal ganglia	eqtl	2.1e-08	+0.62	13:28027857:G:A
Brain Hippocampus	eqtl	2.4e-08	+0.54	13:28027857:G:A
Brain Spinal cord cervical c-1	eqtl	4.2e-08	+0.46	13:28033380:T:C
Small Intestine Terminal Ileum	eqtl	6.4e-08	+0.40	13:28060647:T:C
Adipose Subcutaneous	eqtl	7.5e-08	-0.28	13:28037601:G:A
Esophagus Mucosa	eqtl	4.4e-07	+0.20	13:28020665:T:C
Spleen	eqtl	9.1e-07	+0.43	13:28027514:T:C

FANTOM5 promoters

2 alternative TSS:

Promoter ID	TPM avg	Samples expressed
136527	2.7297	296
136526	0.0509	21

Top tissues by expression

showing 100 of 285 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.25	gold quality
cerebellar hemisphere	UBERON:0002245	81.49	gold quality
cerebellar cortex	UBERON:0002129	81.37	gold quality
monocyte	CL:0000576	81.07	gold quality
mononuclear cell	CL:0000842	80.55	gold quality
leukocyte	CL:0000738	80.03	gold quality
right hemisphere of cerebellum	UBERON:0014890	80.01	gold quality
cerebellum	UBERON:0002037	79.31	gold quality
bone marrow cell	CL:0002092	73.72	silver quality
bone marrow	UBERON:0002371	72.76	gold quality
lymph node	UBERON:0000029	71.18	gold quality
granulocyte	CL:0000094	70.09	gold quality
body of pancreas	UBERON:0001150	69.61	gold quality
spleen	UBERON:0002106	68.87	gold quality
vermiform appendix	UBERON:0001154	68.31	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	67.90	gold quality
gall bladder	UBERON:0002110	66.94	gold quality
pancreas	UBERON:0001264	66.82	gold quality
right lung	UBERON:0002167	66.38	gold quality
blood	UBERON:0000178	66.37	gold quality
pigmented layer of retina	UBERON:0001782	66.30	gold quality
spinal cord	UBERON:0002240	65.24	gold quality
caecum	UBERON:0001153	63.82	gold quality
cerebellar vermis	UBERON:0004720	63.55	silver quality
tibialis anterior	UBERON:0001385	63.36	silver quality
islet of Langerhans	UBERON:0000006	62.86	gold quality
rectum	UBERON:0001052	62.02	gold quality
prefrontal cortex	UBERON:0000451	61.12	gold quality
small intestine Peyer’s patch	UBERON:0003454	61.08	gold quality
epithelial cell of pancreas	CL:0000083	59.89	gold quality
upper leg skin	UBERON:0004262	59.81	gold quality
nephron tubule	UBERON:0001231	59.24	gold quality
small intestine	UBERON:0002108	59.09	gold quality
smooth muscle tissue	UBERON:0001135	58.93	gold quality
secondary oocyte	CL:0000655	58.77	gold quality
right frontal lobe	UBERON:0002810	58.72	gold quality
cingulate cortex	UBERON:0003027	58.32	gold quality
anterior cingulate cortex	UBERON:0009835	58.04	gold quality
primary visual cortex	UBERON:0002436	57.99	gold quality
Brodmann (1909) area 9	UBERON:0013540	57.98	gold quality
neocortex	UBERON:0001950	57.43	gold quality
frontal cortex	UBERON:0001870	57.42	gold quality
colonic epithelium	UBERON:0000397	57.33	silver quality
trabecular bone tissue	UBERON:0002483	57.07	gold quality
hypothalamus	UBERON:0001898	56.70	gold quality
decidua	UBERON:0002450	56.55	gold quality
upper lobe of left lung	UBERON:0008952	56.51	gold quality
renal glomerulus	UBERON:0000074	56.36	silver quality
dorsolateral prefrontal cortex	UBERON:0009834	56.04	gold quality
superficial temporal artery	UBERON:0001614	55.91	gold quality
kidney epithelium	UBERON:0004819	55.86	silver quality
mucosa of stomach	UBERON:0001199	55.85	gold quality
pons	UBERON:0000988	55.84	gold quality
tonsil	UBERON:0002372	55.35	gold quality
upper lobe of lung	UBERON:0008948	55.12	gold quality
paraflocculus	UBERON:0005351	54.62	silver quality
skin of hip	UBERON:0001554	54.56	gold quality
pancreatic ductal cell	CL:0002079	54.34	silver quality
left uterine tube	UBERON:0001303	54.04	gold quality
cerebral cortex	UBERON:0000956	53.92	gold quality
cortical plate	UBERON:0005343	53.80	gold quality
right testis	UBERON:0004534	53.72	gold quality
left testis	UBERON:0004533	53.69	gold quality
pleura	UBERON:0000977	53.65	silver quality
right coronary artery	UBERON:0001625	53.64	gold quality
occipital lobe	UBERON:0002021	53.62	gold quality
transverse colon	UBERON:0001157	53.48	gold quality
parietal pleura	UBERON:0002400	53.34	silver quality
deltoid	UBERON:0001476	53.31	gold quality
testis	UBERON:0000473	53.20	gold quality
hair follicle	UBERON:0002073	53.13	gold quality
intestine	UBERON:0000160	52.80	gold quality
lung	UBERON:0002048	52.70	gold quality
Brodmann (1909) area 46	UBERON:0006483	52.20	gold quality
central nervous system	UBERON:0001017	52.16	gold quality
thymus	UBERON:0002370	52.14	silver quality
substantia nigra	UBERON:0002038	52.08	gold quality
brain	UBERON:0000955	51.73	gold quality
ileal mucosa	UBERON:0000331	51.67	silver quality
cortex of kidney	UBERON:0001225	51.20	gold quality
midbrain	UBERON:0001891	51.03	gold quality
colon	UBERON:0001155	50.99	gold quality
visceral pleura	UBERON:0002401	50.90	gold quality
muscle tissue	UBERON:0002385	50.86	gold quality
quadriceps femoris	UBERON:0001377	50.82	gold quality
large intestine	UBERON:0000059	50.77	gold quality
minor salivary gland	UBERON:0001830	50.69	gold quality
anatomical system	UBERON:0000467	50.66	gold quality
material anatomical entity	UBERON:0000465	50.49	gold quality
multicellular organism	UBERON:0000468	50.49	gold quality
skin of leg	UBERON:0001511	50.47	gold quality
frontal pole	UBERON:0002795	50.41	gold quality
zone of skin	UBERON:0000014	50.33	gold quality
middle frontal gyrus	UBERON:0002702	50.30	gold quality
mucosa of transverse colon	UBERON:0004991	50.30	gold quality
skin of abdomen	UBERON:0001416	50.28	gold quality
Brodmann (1909) area 10	UBERON:0013541	50.18	gold quality
left coronary artery	UBERON:0001626	49.87	gold quality
male germ cell	CL:0000015	49.86	gold quality
esophagus mucosa	UBERON:0002469	49.84	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-MTAB-6678	yes	171.14
E-HCAD-6	yes	29.00
E-ANND-3	yes	10.72
E-MTAB-9801	yes	8.15
E-GEOD-99795	no	21.87

HPA expression

RNA tissue specificity: Tissue enhanced

showing 60 of 68 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM
Corpus callosum	tissue	14.0
Spinal cord	tissue	12.6
Pons	tissue	12.5
Midbrain	tissue	12.5
Medulla oblongata	tissue	12.4
Thalamus	tissue	11.0
Superior colliculi	tissue	10.9
Cerebellum	tissue	10.1
Substantia nigra	tissue	8.8
Periaqueductal gray	tissue	7.7
Hypothalamus	tissue	7.6
Lymph node	tissue	6.1
Cerebral cortex	tissue	5.7
Somatosensory cortex	tissue	5.7
Occipital cortex	tissue	5.6
Spleen	tissue	5.3
Bone marrow	tissue	5.0
Thymus	tissue	4.3
Septum	tissue	4.3
Ventral forebrain	tissue	4.0
Retrosplenial cortex	tissue	4.0
Hippocampal formation	tissue	3.9
Retrosplenial and cingulate cortex	tissue	3.9
Motor cortex	tissue	3.8
Prefrontal cortex	tissue	3.5
Tonsil	tissue	3.4
Olfactory bulb	tissue	3.4
Entorhinal cortex	tissue	3.3
Insular cortex	tissue	3.3
Temporal cortex	tissue	3.0
Amygdala	tissue	2.8
Appendix	tissue	2.8
Putamen	tissue	2.7
Pancreas	tissue	2.6
Postcentral gyrus	tissue	2.0
Locus coeruleus	tissue	1.8
Frontal cortex	tissue	1.7
Gallbladder	tissue	1.5
Breast	tissue	1.4
Kidney	tissue	1.4
Urinary bladder	tissue	1.2
Basal ganglia	tissue	1.2
Small intestine	tissue	0.9
Smooth muscle	tissue	0.8
Caudate putamen	tissue	0.8
Skin 1	tissue	0.7
Rectum	tissue	0.7
Colon	tissue	0.7
Stomach 1	tissue	0.6
Esophagus	tissue	0.6
Adipose tissue	tissue	0.5
Cervix	tissue	0.4
Testis	tissue	0.4
Choroid plexus	tissue	0.4
Lung	tissue	0.4
Liver	tissue	0.4
Nucleus accumbens	tissue	0.3
Seminal vesicle	tissue	0.2
Salivary gland	tissue	0.2
Endometrium 1	tissue	0.2

Brain sub-regions (HPA Brain Atlas): detected in 189; highest nTPM — White matter (14.0), Ventral spinal cord (12.6), Dorsal spinal cord (11.6), Cerebellar cortex (10.7), Flocculonodular lobe (9.6).

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

19 targets:

Target	Regulation
BCL2L1	Activation
BCL2L11	Repression
CDKN1A	Activation
CDKN1B	Repression
CEBPA	Unknown
CEBPB	Repression
CISH	Activation
FZD4	Unknown
ID1	Activation
PARP1	Activation
PIM1	Activation
PIM2	Activation
PTPN6	Unknown
RAD51	Activation
SOCS2	Activation
SOCS3	Activation
SPI1	Unknown
USP22	Activation
XRCC5	Activation

Upstream regulators (CollecTRI, top): CEBPA, HES1, HOXA9, IKZF1, KAT6B, MEIS1, MYB, NCOR1, PAX5, PML, RUNX1, SPI1, STAT3, TXK

miRNA regulators (miRDB)

Targeting FLT3 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 56 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-139-5P	99.80	69.50	1399

Functional genomics

gnomAD constraint: pLI 0.997, LOEUF 0.468, missense Z 1.55 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000241453 — one region, missense o/e 0.90.

Literature-anchored findings (GeneRIF, showing 40)

• First report of D835X mutations in human. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. (PMID:11290608)
• Flt3/Flk-2-ligand in synergy with thrombopoietin may slow down megakaryocyte development by causing increased proliferation of megakaryocyte progenitor cells. (PMID:11983110)
• induces acute promyelocytic leukemia in a mouse model (PMID:12060771)
• Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia (PMID:12070009)
• duplicated in relapsed acute myeloid leukemia (PMID:12239146)
• mutations occur in paired presentation and relapse samples from patients with acute myeloid leukemia (PMID:12239147)
• 767 of 6586 genes differed in expression between FLT3-WT- and FLT-ITD(internal tandem duplication)-expressing cell lines. ITD mutations of Flt3 activate transcriptional programs that partially mimic IL-3 activity. (PMID:12468433)
• Internal tandem duplication of the Flt3 gene appearing or altering at time of AML relapse suggests Flt3-gene abnormalities are very important in the pathogenesis of chemotherapy-resistant AML (PMID:12481903)
• The striking difference in flt3 and c-kit expression on hematopoietic stem cells translated into a corresponding difference in flt3 and c-kit function because FL was more efficient than SCF at supporting the survival of HSCs (PMID:12676789)
• Intracellular signaling initiated by Flt3 ligation modulates the functional phenotype for native human AML blasts both with and without genetic Flt3 abnormalities. (PMID:12681969)
• FLT3 mutations that lead to constitutive receptor activation and confer a poor prognosis in AML (PMID:12691136)
• FLT3/ITD is less common in pediatric than in adult acute myeloid leukemia and FLT3/ITD is a strong and independent adverse prognostic factor, and high ratios between mutant and WT-FLT3 further compromise prognosis. (PMID:12816873)
• antiapoptotic pathways from FLT3 with internal tandem duplication are more divergent than those from WtFLT3 (PMID:12842996)
• Mutations in the FLT3 gene are common in AML, including tandem repeats or a mutation in the kinase domain. (PMID:12854887)
• No significant correlation was found between FLT3 mutations and high levels of MDR1 in acute myeloid leukemia. (PMID:12926083)
• REVIEW: The role of FLT3 mutations in APL and other AML (PMID:12935959)
• wtFLT3 is often constitutively activated by FLT3 ligand in AML and thus, like its mutated form, might contribute to the altered signaling that characterizes leukemogenesis. (PMID:12969963)
• FLT3-D835/I836 mutations are one of the second genetic events in infant ALL with MLL rearrangements or pediatric ALL with hyperdiploidy (PMID:14504097)
• reduced AML1 activities predispose cells to the acquisition of the activating FLT3 mutation as a secondary event leading to full transformation in acute myeloblastic leukemia M0 (PMID:14562119)
• distinct activating FLT3-TKD mutations at position D835 mediate primary resistance to FLT3 PTK inhibitors in FLT3-transformed cell lines (PMID:14604974)
• FLT3 mutations are associated with molecular lesions in acute myeloid leukemias (PMID:14630076)
• Phosphorylation is inhibited by SU11248 in acute myeloid leukemia. (PMID:14654525)
• search for the presence of FLT3 mutations in leukemic blasts from 71 patients with childhood acute lymphoblastic leukemia discovered three novel in-frame deletions within a 7-amino acid region of the receptor juxtamembrane domain. (PMID:14670924)
• FLT3 analysis shows the autoinhibitory conformation of its complete juxtamembrane domain (PMID:14759363)
• FLT3 Asp(835) mutations may have a role in relapse of acute myeloid leukemia (PMID:14977832)
• FLT3 can negatively regulate Foxo transcription factors, thereby promoting cell survival and proliferation. (PMID:14981546)
• Mutations of Flt3 may disrupt transcriptional repressor function resulting in aberrant gene regulation and abnormal leukemia cell growth. (PMID:14982881)
• Activating mutations in the FLT3 RTK gene were found in each of 3 CD117/KIT(+) cases that were analyzed, but not in 52 other adult T-acute lymphoblastic leukemia (PMID:15044257)
• CXCR-4 expression was significantly higher in fetal liver tyrosine kinase-3 (Flt3)/internal tandem duplication (ITD) acute myeloid leukemia (PMID:15054042)
• Internal tandem duplication of the juxtamembrane domain or by activating point mutations in the second tyrosine kinase domain in FLT3 are associated with leukocytosis and the monocytic FAB subtypes M4 and M5. (PMID:15059064)
• Flt3 mutations identify patients at high risk of relapse (PMID:15061200)
• FLT3/internal tandem duplication(ITD) mutations confer a particularly poor prognosis in pediatric acute myelogenous leukemia patients (PMID:15166029)
• high frequency of FLT3 mutations in adult acute myelocytic leukemia without recurrent cytogenetic translocations. (PMID:15167911)
• FLT3 autoinhibited structure showed that N841 is the key residue in a hydrogen-bonding network that likely stabilizes the activation loop (PMID:15178581)
• Wild-type Flt3-overexpressing CD34+ cells exposed to high levels of its physiologic ligand did not produce early cobblestone areas (PMID:15242879)
• FLT3 has roles in different signal transduction pathways that control proliferation, survival and other processes in hematopoietic cells [review] (PMID:15253381)
• The loss of a clone with a mutation in the FLT3 gene at relapse did not improve the prognosis. (PMID:15289019)
• Inspection of the FLT3 structure revealed that Y842 is the key residue in regulating the switch from the closed to the open (= active) conformation of the FLT3 activation loop (PMID:15345593)
• mutations of specific residues located in the activation loop (D835X and 836-deletion in Flt-3; D816V in c-Kit) as well as a 6-base pair (6-bp) insertion at residue 840 in Flt-3 operate in a similar way (PMID:15363457)
• transformation of TF-1 cells with FLT3/ITD mutations suppressed the activity of SHP-1 by approximately 3-fold (PMID:15574429)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Flt3	ENSMUSG00000042817
rattus_norvegicus	Flt3	ENSRNOG00000054764

Paralogs (53): INSRR (ENSG00000027644), MUSK (ENSG00000030304), FLT4 (ENSG00000037280), EPHA3 (ENSG00000044524), ROS1 (ENSG00000047936), LTK (ENSG00000062524), ERBB3 (ENSG00000065361), TIE1 (ENSG00000066056), FGFR2 (ENSG00000066468), FGFR3 (ENSG00000068078), EPHA8 (ENSG00000070886), FGFR1 (ENSG00000077782), EPHA6 (ENSG00000080224), TYRO3 (ENSG00000092445), FLT1 (ENSG00000102755), MET (ENSG00000105976), EPHB6 (ENSG00000106123), PDGFRB (ENSG00000113721), EPHA4 (ENSG00000116106), TEK (ENSG00000120156), KDR (ENSG00000128052), EPHB2 (ENSG00000133216), PDGFRA (ENSG00000134853), EPHA7 (ENSG00000135333), IGF1R (ENSG00000140443), NTRK3 (ENSG00000140538), ERBB2 (ENSG00000141736), EPHA2 (ENSG00000142627), EPHA5 (ENSG00000145242), EGFR (ENSG00000146648), EPHA1 (ENSG00000146904), NTRK2 (ENSG00000148053), MERTK (ENSG00000153208), EPHB1 (ENSG00000154928), KIT (ENSG00000157404), FGFR4 (ENSG00000160867), DDR2 (ENSG00000162733), RYK (ENSG00000163785), MST1R (ENSG00000164078), LMTK2 (ENSG00000164715), RET (ENSG00000165731), AXL (ENSG00000167601), ROR2 (ENSG00000169071), ALK (ENSG00000171094), INSR (ENSG00000171105), ERBB4 (ENSG00000178568), CSF1R (ENSG00000182578), EPHB3 (ENSG00000182580), EPHA10 (ENSG00000183317), ROR1 (ENSG00000185483), EPHB4 (ENSG00000196411), NTRK1 (ENSG00000198400), DDR1 (ENSG00000204580)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:95559) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 79 distinct phenotype terms.

Mouse phenotype (MP)	Records
increased leukocyte cell number	3
enlarged spleen	3
abnormal definitive hematopoiesis	3
abnormal B cell differentiation	3
increased monocyte cell number	2
extramedullary hematopoiesis	2
increased bone marrow cell number	2
increased granulocyte number	2
abnormal spleen morphology	2
arrested B cell differentiation	2
premature death	2
decreased B cell number	2
decreased NK cell number	2
increased pro-B cell number	2
decreased pre-B cell number	2
intermingled spleen red and white pulp	2
increased spleen white pulp amount	2
abnormal bone marrow cell number	1
increased neutrophil cell number	1
decreased leukocyte cell number	1
decreased neutrophil cell number	1
abnormal heart morphology	1
enlarged heart	1
decreased bone marrow cell number	1
abnormal skeletal muscle morphology	1

+54 more (showing top 25).

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Bos taurus	P43481	99.4%	Diamond
Capra hircus	Q28317	99.4%	Diamond
Felis catus	Q28889	99.2%	Diamond
Canis lupus familiaris	O97799	98.4%	Diamond
Sus scrofa	Q2HWD6	98.1%	Diamond
Callithrix jacchus	Q76II0	94.6%	Diamond
Gallus gallus	P18461	92.7%	Diamond
Notophthalmus viridescens	Q91147	87.9%	Diamond
Pleurodeles waltl	Q91285	87.8%	Diamond
Danio rerio	O73791	81.5%	Diamond
Coturnix coturnix	Q90330	81.0%	Diamond
Xenopus laevis	P22182	80.6%	Diamond
Takifugu rubripes	Q8AXC7	73.2%	Diamond
Coturnix japonica	P52583	73.1%	Diamond
Ciona intestinalis	Q4H3K6	60.1%	Diamond
Halocynthia roretzi	Q95YM9	59.9%	Diamond
Drosophila melanogaster	Q09147	55.0%	Diamond
Dugesia japonica	Q8MY86	51.0%	Diamond
Hydra vulgaris	Q86PM4	50.2%	Diamond
Caenorhabditis elegans	Q21038	49.5%	Diamond
Strongylocentrotus purpuratus	Q26614	46.4%	Diamond
Bombyx mori	D2IYS2	44.0%	Diamond
Feline sarcoma virus (STRAIN HARDY-ZUCKERMAN 4)	P04048	99.2%	Diamond
Feline sarcoma virus (STRAIN MCDONOUGH)	P00545	99.1%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
PAN3	protein-coding	255967
PAN3-AS1	ncRNA	100288730
URAD	protein-coding	646625
LINC00543	ncRNA	100132234
CDX2	protein-coding	1045
FLT1	protein-coding	2321

Protein

Protein identifiers

Receptor-type tyrosine-protein kinase FLT3 — P36888 (reviewed: P36888)

Alternative names: FL cytokine receptor, Fetal liver kinase-2, Fms-like tyrosine kinase 3, Stem cell tyrosine kinase 1

All UniProt accessions (2): E7ER61, P36888

UniProt curated annotations — full annotation on UniProt →

Function. Tyrosine-protein kinase that acts as a cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Promotes phosphorylation of FES, FER, PTPN6/SHP, PTPN11/SHP-2, PLCG1, and STAT5A and/or STAT5B. Activation of wild-type FLT3 causes only marginal activation of STAT5A or STAT5B. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.

Subunit / interactions. Monomer in the absence of bound FLT3LG. Homodimer in the presence of bound FLT3LG. Interacts with FIZ1 following ligand activation. Interacts with FES, FER, LYN, FGR, HCK, SRC and GRB2. Interacts with PTPRJ/DEP-1 and PTPN11/SHP2. Interacts with RNF115 and RNF126. (Microbial infection) Interacts with human cytomegalovirus protein UL7.

Subcellular location. Membrane. Endoplasmic reticulum lumen.

Tissue specificity. Detected in bone marrow, in hematopoietic stem cells, in myeloid progenitor cells and in granulocyte/macrophage progenitor cells (at protein level). Detected in bone marrow, liver, thymus, spleen and lymph node, and at low levels in kidney and pancreas. Highly expressed in T-cell leukemia.

Post-translational modifications. N-glycosylated, contains complex N-glycans with sialic acid. Autophosphorylated on several tyrosine residues in response to FLT3LG binding. FLT3LG binding also increases phosphorylation of mutant kinases that are constitutively activated. Dephosphorylated by PTPRJ/DEP-1, PTPN1, PTPN6/SHP-1, and to a lesser degree by PTPN12. Dephosphorylation is important for export from the endoplasmic reticulum and location at the cell membrane. Rapidly ubiquitinated by UBE2L6 and the E3 ubiquitin-protein ligase SIAH1 after autophosphorylation, leading to its proteasomal degradation.

Disease relevance. Leukemia, acute myelogenous (AML) [MIM:601626] A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes. The gene represented in this entry may be involved in disease pathogenesis. Somatic mutations that lead to constitutive activation of FLT3 are frequent in AML patients. These mutations fall into two classes, the most common being in-frame internal tandem duplications of variable length in the juxtamembrane region that disrupt the normal regulation of the kinase activity. Likewise, point mutations in the activation loop of the kinase domain can result in a constitutively activated kinase.

Activity regulation. Present in an inactive conformation in the absence of bound ligand. FLT3LG binding leads to dimerization and activation by autophosphorylation.

Domain organisation. The juxtamembrane autoregulatory region is important for normal regulation of the kinase activity and for maintaining the kinase in an inactive state in the absence of bound ligand. Upon tyrosine phosphorylation, it mediates interaction with the SH2 domains of numerous signaling partners. In-frame internal tandem duplications (ITDs) result in constitutive activation of the kinase. The activity of the mutant kinase can be stimulated further by FLT3LG binding.

Miscellaneous. Can be used as diagnostic tool to establish the exact cause of acute myeloid leukemia, and to determine the optimal therapy.

Similarity. Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
P36888-1	1	yes
P36888-2	2

RefSeq proteins (1): NP_004110* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR001245	Ser-Thr/Tyr_kinase_cat_dom	Domain
IPR001824	Tyr_kinase_rcpt_3_CS	Conserved_site
IPR007110	Ig-like_dom	Domain
IPR008266	Tyr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR013151	Immunoglobulin_dom	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR020635	Tyr_kinase_cat_dom	Domain
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050122	RTK	Family

Pfam: PF00047, PF07714

Enzyme classification (BRENDA)

• EC 2.7.10.1 — receptor protein-tyrosine kinase (BRENDA: 44 organisms, 214 substrates, 574 inhibitors, 11 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

4 substrates with measured Km, best-characterized 4. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.0011–0.129	4
AC-DYFE-6-CHLORO-W-NHME	0.0051	1
AC-DYFGW-NHME	0.07	1
YFEW	0.232	1

Catalyzed reactions (Rhea)

• L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H(+) (RHEA:10596)

UniProt features (103 total): helix 18, strand 16, sequence variant 14, modified residue 13, glycosylation site 10, disulfide bond 7, sequence conflict 6, mutagenesis site 4, turn 3, binding site 2, topological domain 2, domain 2, signal peptide 1, chain 1, transmembrane region 1, splice variant 1, region of interest 1, active site 1

Structure

Experimental structures (PDB)

11 structures by resolution:

PDB	Title	Method	Resolution (Å)
1RJB	Crystal Structure of FLT3	X-RAY DIFFRACTION	2.1
6JQR	Crystal structure of FLT3 in complex with gilteritinib	X-RAY DIFFRACTION	2.2
5X02	Crystal structure of the FLT3 kinase domain bound to the inhibitor FF-10101	X-RAY DIFFRACTION	2.4
6IL3	Crystal structure of the FLT3 kinase bound to a small molecule inhibitor	X-RAY DIFFRACTION	2.5
8XB1	Crystal structure of FLT3 in complex with a Pyrazinamide Macrocycle derivative	X-RAY DIFFRACTION	2.85
4RT7	Crystal Structure of FLT3 with a small molecule inhibitor	X-RAY DIFFRACTION	3.1
4XUF	Crystal structure of the FLT3 kinase domain bound to the inhibitor quizartinib (AC220)	X-RAY DIFFRACTION	3.2
7QDP	Crystal structure of FLT3 T343I in complex with the canonical ligand FL	X-RAY DIFFRACTION	3.69
3QS7	Crystal structure of a human Flt3 ligand-receptor ternary complex	X-RAY DIFFRACTION	4.3
7ZV9	Crystal structure of FLT3 in complex with a monomeric FLT3 Ligand variant	X-RAY DIFFRACTION	4.51
3QS9	Crystal structure of a human Flt3 ligand-receptor ternary complex	X-RAY DIFFRACTION	7.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P36888-F1	76.19	0.30

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Transferases, Kinases, Tyr protein kinases, CD markers, Predicted membrane proteins, RAS pathway related proteins, Cancer-related genes, Mutated cancer genes, Mutational cancer driver genes, Disease related genes, FDA approved drug targets, Small molecule drugs, Human disease related genes

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): endoplasmic reticulum

Antibody reliability (HPA): IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1)

Position	Role
811	proton acceptor

Ligand- & substrate-binding residues (2)

Position	Role
644	ATP
616–624	ATP

Post-translational modifications (13)

Type	Positions
Phosphotyrosine	572, 589, 591, 599, 726, 768, 793, 842, 955, 969
Phosphoserine	574, 759, 993

Disulfide bonds (7)

Type	Positions
Disulfide bond	35–65, 103–114, 199–206, 232–241, 272–330, 368–407, 381–392

Glycosylation sites (10)

Type	Positions
N-linked (glcnac…) asparagine	43, 100, 151, 306, 323, 351, 354, 473, 502, 541

Mutagenesis-validated functional residues (4)

Position	Phenotype
589	reduced phosphorylation of the wild-type kinase in response to ligand binding. no effect on the phosphorylation of the constitutively …
591	no significant effect on tyrosine phosphorylation. abolishes activation of stat5a.
599	abolishes interaction with ptpn11/shp2 and phosphorylation of ptpn11/shp2.
644	abolishes kinase activity.

Function

Pathways and Gene Ontology

Reactome pathways

23 curated (TAS) of 46; 24 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

46 pathways:

ID	Pathway	Evidence
R-HSA-2219530	Constitutive Signaling by Aberrant PI3K in Cancer ⚕	curated
R-HSA-9702509	FLT3 mutants bind TKIs ⚕	curated
R-HSA-9706377	FLT3 signaling by CBL mutants ⚕	curated
R-HSA-9702569	KW2449-resistant FLT3 mutants ⚕	curated
R-HSA-9702518	STAT5 activation downstream of FLT3 ITD mutants ⚕	curated
R-HSA-9702581	crenolanib-resistant FLT3 mutants ⚕	curated
R-HSA-9702590	gilteritinib-resistant FLT3 mutants ⚕	curated
R-HSA-9702596	lestaurtinib-resistant FLT3 mutants ⚕	curated
R-HSA-9702998	linifanib-resistant FLT3 mutants ⚕	curated
R-HSA-9702600	midostaurin-resistant FLT3 mutants ⚕	curated
R-HSA-9702605	pexidartinib-resistant FLT3 mutants ⚕	curated
R-HSA-9702614	ponatinib-resistant FLT3 mutants ⚕	curated
R-HSA-9702620	quizartinib-resistant FLT3 mutants ⚕	curated
R-HSA-9702577	semaxanib-resistant FLT3 mutants ⚕	curated
R-HSA-9702624	sorafenib-resistant FLT3 mutants ⚕	curated
R-HSA-9702632	sunitinib-resistant FLT3 mutants ⚕	curated
R-HSA-9703009	tamatinib-resistant FLT3 mutants ⚕	curated
R-HSA-9702636	tandutinib-resistant FLT3 mutants ⚕	curated
R-HSA-9706369	Negative regulation of FLT3	curated
R-HSA-109704	PI3K Cascade	curated
R-HSA-6811558	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	curated
R-HSA-1257604	PIP3 activates AKT signaling	curated
R-HSA-5673001	RAF/MAP kinase cascade	curated
R-HSA-1643685	Disease ⚕	—
R-HSA-5663202	Diseases of signal transduction by growth factor receptors and second messengers ⚕	—
R-HSA-9702506	Drug resistance of FLT3 mutants ⚕	—
R-HSA-9682385	FLT3 signaling in disease ⚕	—
R-HSA-2219528	PI3K/AKT Signaling in Cancer ⚕	—
R-HSA-9703648	Signaling by FLT3 ITD and TKD mutants ⚕	electronic
R-HSA-1280215	Cytokine Signaling in Immune system	—
R-HSA-9607240	FLT3 Signaling	electronic
R-HSA-9706374	FLT3 signaling through SRC family kinases	electronic
R-HSA-2428924	IGF1R signaling cascade	—
R-HSA-112399	IRS-mediated signalling	—
R-HSA-2428928	IRS-related events triggered by IGF1R	—
R-HSA-168256	Immune System	—
R-HSA-74751	Insulin receptor signalling cascade	—
R-HSA-9006925	Intracellular signaling by second messengers	—
R-HSA-5683057	MAPK family signaling cascades	—
R-HSA-5684996	MAPK1/MAPK3 signaling	—
R-HSA-199418	Negative regulation of the PI3K/AKT network	—
R-HSA-9645135	STAT5 Activation	electronic
R-HSA-162582	Signal Transduction	—
R-HSA-74752	Signaling by Insulin receptor	—
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	—
R-HSA-2404192	Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	—

MSigDB gene sets: 0 (showing top):

GO Biological Process (26): leukocyte homeostasis (GO:0001776), myeloid progenitor cell differentiation (GO:0002318), pro-B cell differentiation (GO:0002328), cell surface receptor protein tyrosine kinase signaling pathway (GO:0007169), positive regulation of cell population proliferation (GO:0008284), cell migration (GO:0016477), peptidyl-tyrosine phosphorylation (GO:0018108), cytokine-mediated signaling pathway (GO:0019221), hemopoiesis (GO:0030097), B cell differentiation (GO:0030183), common myeloid progenitor cell proliferation (GO:0035726), positive regulation of tyrosine phosphorylation of STAT protein (GO:0042531), regulation of apoptotic process (GO:0042981), positive regulation of MAP kinase activity (GO:0043406), positive regulation of MAPK cascade (GO:0043410), lymphocyte proliferation (GO:0046651), protein autophosphorylation (GO:0046777), positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0051897), cellular response to cytokine stimulus (GO:0071345), cellular response to glucocorticoid stimulus (GO:0071385), dendritic cell differentiation (GO:0097028), liver regeneration (GO:0097421), protein phosphorylation (GO:0006468), cell surface receptor signaling pathway (GO:0007166), positive regulation of macromolecule metabolic process (GO:0010604), vascular endothelial growth factor signaling pathway (GO:0038084)

GO Molecular Function (15): protein tyrosine kinase activity (GO:0004713), transmembrane receptor protein tyrosine kinase activity (GO:0004714), cytokine receptor activity (GO:0004896), vascular endothelial growth factor receptor activity (GO:0005021), ATP binding (GO:0005524), growth factor binding (GO:0019838), nuclear glucocorticoid receptor binding (GO:0035259), protein-containing complex binding (GO:0044877), phosphatidylinositol 3-kinase activator activity (GO:0141038), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), transmembrane signaling receptor activity (GO:0004888), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (6): endoplasmic reticulum lumen (GO:0005788), plasma membrane (GO:0005886), endosome membrane (GO:0010008), signaling receptor complex (GO:0043235), membrane (GO:0016020), protein-containing complex (GO:0032991)

Reactome top-level categories

10 top-level categories:

Category	Pathways
Drug resistance of FLT3 mutants	11
IRS-mediated signalling	1
Intracellular signaling by second messengers	1
PI3K/AKT Signaling in Cancer	1
MAPK1/MAPK3 signaling	1
Negative regulation of the PI3K/AKT network	1
Cytokine Signaling in Immune system	1
FLT3 Signaling	1
FLT3 signaling in disease	1
Signaling by FLT3 ITD and TKD mutants	1

GO top-level categories

showing 60 of 69 GO namespaces:

Category	Terms
cell population proliferation	2
protein phosphorylation	2
positive regulation of intracellular signal transduction	2
binding	2
immune system process	1
homeostasis of number of cells	1
hematopoietic progenitor cell differentiation	1
lymphoid progenitor cell differentiation	1
enzyme-linked receptor protein signaling pathway	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
cell motility	1
cell surface receptor signaling pathway	1
cellular response to cytokine stimulus	1
cell development	1
lymphocyte differentiation	1
B cell activation	1
tyrosine phosphorylation of STAT protein	1
regulation of tyrosine phosphorylation of STAT protein	1
positive regulation of peptidyl-tyrosine phosphorylation	1
apoptotic process	1
regulation of programmed cell death	1
MAP kinase activity	1
regulation of MAP kinase activity	1
positive regulation of MAPK cascade	1
positive regulation of protein serine/threonine kinase activity	1
MAPK cascade	1
regulation of MAPK cascade	1
mononuclear cell proliferation	1
lymphocyte activation	1
phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	1
response to cytokine	1
response to glucocorticoid	1
cellular response to corticosteroid stimulus	1
protein kinase activity	1
protein tyrosine kinase activity	1
transmembrane receptor protein kinase activity	1
transmembrane signaling receptor activity	1
cytokine-mediated signaling pathway	1
cytokine binding	1
immune receptor activity	1
transmembrane receptor protein tyrosine kinase activity	1
vascular endothelial growth factor signaling pathway	1
vascular endothelial growth factor binding	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
anion binding	1
protein binding	1
nuclear receptor binding	1
phosphatidylinositol 3-kinase regulator activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
signaling receptor activity	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
endoplasmic reticulum	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 1 of 47 annotations. The rest are phylogenetic / computational / electronic (IEA).

1 experimentally-supported GO terms:

GO term	NS	Evidence
hemopoiesis	BP	direct assay

Protein interactions and networks

STRING

showing 15 of 2,904 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FLT3	NPM1	P06748	930
FLT3	CD34	P28906	865
FLT3	FLT3LG	P49771	863
FLT3	ASXL1	Q8IXJ9	862
FLT3	DNMT3A	Q9Y6K1	844
FLT3	TET2	Q6N021	840
FLT3	IL7R	P16871	822
FLT3	SLAMF1	Q13291	820
FLT3	IDH1	O75874	800
FLT3	CEBPA	P49715	800
FLT3	RUNX1	Q01196	800
FLT3	IL3	P08700	798
FLT3	KITLG	P21583	792
FLT3	IDH2	P48735	792
FLT3	PHF6	Q8IWS0	780

IntAct

Human interaction partners of FLT3 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

22 partners by confidence:

Partner	Interaction type	MIscore	Records
SYK	direct interaction	0.740	22
GRB10	physical association	0.590	6
ABL2	direct interaction	0.540	3
PTPN11	association	0.460	2
ABL1	direct interaction	0.440	2
CRK	direct interaction	0.440	2
CRKL	direct interaction	0.440	2
FYN	direct interaction	0.440	2
LCK	direct interaction	0.440	2
RASA1	direct interaction	0.440	2
BLK	direct interaction	0.440	1
FLT3LG	direct interaction	0.440	1
SOCS6	direct interaction	0.440	1
TNS1	direct interaction	0.440	1
YES1	direct interaction	0.440	1
PIK3R1	physical association	0.400	2
MRPS28	physical association	0.400	1
CLGN	association	0.350	1
LANCL1	association	0.350	1
PTPRJ	proximity	0.270	3
KIF2A	proximity	0.270	1
IKBKG	direct interaction	0.000	2

BioGRID (330 interactions; top human partners by supporting records): CBL (Affinity Capture-Western; 3 records), CTNNB1 (Affinity Capture-Western; 3 records), PTPN11 (Reconstituted Complex; 3 records), SLA (Affinity Capture-Western; 3 records), CALM3 (Affinity Capture-MS; 2 records), HSPA1B (Affinity Capture-MS; 2 records), PIK3R1 (Affinity Capture-Western; 2 records), PPAN (Positive Genetic; 2 records), SIAH1 (Reconstituted Complex; 2 records), SOCS1 (Affinity Capture-MS; 2 records), SOCS2 (Affinity Capture-Western; 2 records), UBE2L6 (Affinity Capture-Western; 2 records), ABCG5 (Positive Genetic), ADCK3 (Proximity Label-MS), AFG3L2 (Proximity Label-MS)

SIGNOR signaling

showing 50 of 115 signaling interactions:

A	Effect	B	Mechanism
FLT3	up-regulates	FLT3	phosphorylation
sunitinib	down-regulates	FLT3	“chemical inhibition”
anthra[1,9-cd]pyrazol-6(2H)-one	down-regulates	FLT3	“chemical inhibition”
CHIR-124	down-regulates	FLT3	“chemical inhibition”
4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1,3-dihydrobenzimidazol-2-ylidene]-2-quinolinone	down-regulates	FLT3	“chemical inhibition”
“dovitinib; bis(lactic acid)”	down-regulates	FLT3	“chemical inhibition”
[4-[2-(1H-indazol-3-yl)ethenyl]phenyl]-(1-piperazinyl)methanone	down-regulates	FLT3	“chemical inhibition”
MK-2461	down-regulates	FLT3	“chemical inhibition”
FLT3	up-regulates	Skeletal_muscle_differentiation
quizartinib	down-regulates	FLT3	“chemical inhibition”
tandutinib	down-regulates	FLT3	“chemical inhibition”
TG101209	down-regulates	FLT3	“chemical inhibition”
FLT3	“up-regulates activity”	AKT
FLT3	“down-regulates quantity by repression”	CEBPA	“transcriptional regulation”
FLT3	“up-regulates activity”	SHC1	phosphorylation
FLT3	“up-regulates activity”	AKT1
FLT3	“up-regulates activity”	RUNX1
sunitinib	“down-regulates activity”	FLT3	“chemical inhibition”
regorafenib	“down-regulates activity”	FLT3	“chemical inhibition”
PIM1	“up-regulates quantity”	FLT3	phosphorylation
FLT3	“down-regulates quantity”	PTPN6	“transcriptional regulation”
FLT3	“up-regulates activity”	Glycolysis
FLT3	“up-regulates activity”	CTNNB1	phosphorylation
FLT3	“up-regulates activity”	ERK1/2
FLT3	“up-regulates activity”	HK2
FLT3	“down-regulates quantity by repression”	PTPN6	“transcriptional regulation”
FLT3	“up-regulates quantity by stabilization”	SIRT1	“post transcriptional regulation”
FLT3	“up-regulates quantity by expression”	MYC
FLT3	“up-regulates quantity by expression”	USP22	“transcriptional regulation”
cabozantinib	“down-regulates activity”	FLT3	“chemical inhibition”
FLT3	“up-regulates activity”	ACAT1	phosphorylation
FLT3	“down-regulates activity”	IDH2	phosphorylation
FLT3	“up-regulates activity”	Hexokinase
FLT3	“up-regulates activity”	FLT3	phosphorylation
PTPRJ	“down-regulates activity”	FLT3	dephosphorylation
SYK	“up-regulates activity”	FLT3	phosphorylation
FYN	“up-regulates activity”	FLT3	phosphorylation
FLT3LG	up-regulates	FLT3	binding
FLT3	“up-regulates activity”	PTPN11	binding
FLT3	“up-regulates activity”	GRB2	binding
FLT3	“up-regulates activity”	STAT5A	phosphorylation
FLT3	“up-regulates quantity by expression”	ID1	“transcriptional regulation”
CBL	“down-regulates activity”	FLT3	binding
FLT3	“up-regulates quantity by expression”	miR-155	“transcriptional regulation”
FLT3	“up-regulates activity”	GRB10	binding
SLA2	“down-regulates activity”	FLT3	binding
FLT3	“up-regulates activity”	PIK3R1
FLT3	“up-regulates activity”	PI3K
CBLB	“down-regulates activity”	FLT3	ubiquitination
FLT3	“up-regulates quantity by expression”	FZD4	“transcriptional regulation”

Protein complexes (CORUM) (5)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

5 complexes by size:

Complex	Subunits	Members
★ FLT3-FLT3LG complex	2	FLT3LG, FLT3
★ FLT3-SET complex	2	FLT3, SET
★ CDKN1B-FLT3 complex	2	CDKN1B, FLT3
★ FES-FLT3 complex	2	FES, FLT3
★ FER-FLT3 complex	2	FER, FLT3

Ligand–receptor pairs (CellPhoneDB) (1)

Curated ligand–receptor partners (cell-cell communication), distinct from the protein–protein interactions above.

1 ligand–receptor pairs:

Partner	This gene’s role	Signaling class
FLT3LG	receptor

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 22 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Regulation of signaling by CBL	6	156.8×	1e-10
FLT3 Signaling	8	145.7×	5e-14
Downstream signal transduction	5	100.2×	7e-08
Signaling by SCF-KIT	7	91.5×	9e-11
GPVI-mediated activation cascade	5	81.2×	2e-07
FCGR3A-mediated phagocytosis	5	49.3×	1e-06
Constitutive Signaling by Aberrant PI3K in Cancer	5	33.4×	6e-06
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	5	25.5×	2e-05

GO biological processes:

GO term	Partners	Fold	FDR
ephrin receptor signaling pathway	6	93.8×	1e-08
cellular response to transforming growth factor beta stimulus	5	62.8×	2e-06
T cell receptor signaling pathway	6	41.4×	1e-06
intracellular signal transduction	8	13.9×	4e-06

Disease & clinical

Cancer significance

From CIViC — curated cancer-variant interpretation:

FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.

From intOGen — cancer-driver classification: activating (oncogene-like) across 2 cancer types — ALL, AML.

intOGen’s role is a computational inference from cohort mutation patterns and may diverge from the gene’s curated/literature role; read it alongside the evidence above.

Genetic variants

Variant evidence for FLT3: 247 ClinVar records (14 pathogenic / likely pathogenic); 20 CIViC cancer variants; 1 PharmGKB clinical annotation; 63 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

247 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	10
Likely pathogenic	4
Uncertain significance	80
Likely benign	40
Benign	85

Top pathogenic / likely-pathogenic (14)

Showing all 14 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
219096	NM_004119.3(FLT3):c.1773_1793dup (p.Tyr597_Glu598insAspValAspPheArgGluTyr)	Pathogenic	criteria provided, single submitter	1
2572500	NM_004119.3(FLT3):c.2533A>G (p.Arg845Gly)	Likely pathogenic	criteria provided, single submitter	1
4528371	NM_004119.3(FLT3):c.1715A>G (p.Tyr572Cys)	Likely pathogenic	criteria provided, single submitter	1
16276	NM_004119.3(FLT3):c.2503G>T (p.Asp835Tyr)	Pathogenic	no assertion criteria provided	3
16272	NM_004119.3(FLT3):c.2504A>T (p.Asp835Val)	Pathogenic	no assertion criteria provided	2
16270	FLT3, INTERNAL TANDEM DUP	Pathogenic	no assertion criteria provided	1
16271	NM_004119.3(FLT3):c.2520_2521insGGATCC (p.Ser840_Asn841insGlySer)	Pathogenic	no assertion criteria provided	1
16273	NM_004119.3(FLT3):c.2503G>C (p.Asp835His)	Pathogenic	no assertion criteria provided	1
16274	NM_004119.3(FLT3):c.2503G>A (p.Asp835Asn)	Pathogenic	no assertion criteria provided	1
16277	NM_004119.3(FLT3):c.2503_2505del (p.Asp835del)	Pathogenic	no assertion criteria provided	1
16278	NM_004119.3(FLT3):c.1777_1779del (p.Asp593del)	Pathogenic	no assertion criteria provided	1
375972	NM_004119.3(FLT3):c.2505T>A (p.Asp835Glu)	Pathogenic	no assertion criteria provided	1
590265	t(13;17)(q12.2;q11.2)	Likely pathogenic	no assertion criteria provided	1
800354	NM_004119.3(FLT3):c.1714T>C (p.Tyr572His)	Likely pathogenic	no assertion criteria provided	1

Per-variant reference — Sugi Variant

Explore FLT3’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 32 predictions of 2,456):

Position(s)	Effect	Δscore	Sites
13:28015588–28015589	donor_loss	1.0000	5
13:28015702–28015703	acceptor_loss	1.0000	5
13:28015714–28015715	acceptor_gain	1.0000	2
13:28023374	donor_gain	1.0000
13:28028176–28028177	donor_loss	1.0000	5
13:28034080–28034081	donor_loss	1.0000	5
13:28034085	donor_gain	1.0000
13:28037293	acceptor_gain	1.0000
13:28062070–28062071	acceptor_loss	1.0000	2
13:28070489–28070490	donor_loss	1.0000	5

AlphaMissense

1,717 missense substitutions predicted likely pathogenic (of 6,557 scored), across 404 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M908	9	0.954	0.997
M855	9	0.951	0.995
M799	9	0.931	0.995
M645	9	0.858	0.957
M922	9	0.853	0.994
N816	8	0.998	0.999
D829	8	0.998	1.000
D811	8	0.997	1.000
H809	8	0.994	0.998
D870	8	0.994	0.998
F621	8	0.989	1.000
F830	8	0.985	0.998
D698	8	0.978	0.996
F882	8	0.975	0.998
F936	8	0.974	0.997
F898	8	0.970	0.998
D787	8	0.962	0.989
F605	8	0.956	0.999
S869	8	0.955	1.000
D835	8	0.934	0.975

HPA cancer prognostics

RNA cancer specificity: Cancer enhanced (Breast Invasive Carcinoma)

Disease associations

OMIM: gene MIM:136351 | disease phenotypes: MIM:601626, MIM:254500

GenCC curated gene-disease

1 curated gene-disease records:

Disease	Classification	Inheritance	Records
leukemia, acute myeloid, susceptibility to	Limited	Autosomal dominant

ClinGen Gene-Disease Validity

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

1 validity classifications:

Disease	Classification	Inheritance
leukemia, acute myeloid, susceptibility to	Limited	AD

Genomics England panels (PanelApp)

Clinical diagnostic gene panels including this gene (1 panels, 0 green/diagnostic-grade). Confidence: green = diagnostic, amber = moderate.

1 panels:

Panel	Rating
Cytopenias and congenital anaemias	amber

Mondo (5): acute myeloid leukemia (MONDO:0018874), acute lymphoblastic leukemia (MONDO:0004967), atypical chronic myeloid leukemia, BCR-ABL1 negative (MONDO:0004653), plasma cell myeloma (MONDO:0009693), leukemia, acute myeloid, susceptibility to (MONDO:0100173)

Orphanet (5): Acute myeloid leukemia (Orphanet:519), Acute lymphoblastic leukemia (Orphanet:513), Atypical chronic myeloid leukemia (Orphanet:98824), Multiple myeloma (Orphanet:29073), AL amyloidosis (Orphanet:85443)

HPO phenotypes

5 phenotypes (HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0001442	Typified by somatic mosaicism
HP:0004808	Acute myeloid leukemia
HP:0006721	Acute lymphoblastic leukemia
HP:0010982	Polygenic inheritance

GWAS associations

showing 30 of 63 associations:

Study	Trait	p-value
GCST90002393_231	Monocyte count	0.000000e+00
GCST90002394_159	Monocyte percentage of white cells	0.000000e+00
GCST004625_31	Monocyte count	3e-240
GCST004609_180	Monocyte percentage of white cells	4e-188
GCST004608_125	Granulocyte percentage of myeloid white cells	2e-136
GCST90002393_236	Monocyte count	4e-117
GCST90002394_160	Monocyte percentage of white cells	1e-109
GCST90002393_232	Monocyte count	5e-92
GCST90002407_445	White blood cell count	4e-83
GCST90002394_164	Monocyte percentage of white cells	4e-68
GCST004625_32	Monocyte count	2e-41
GCST90002393_234	Monocyte count	2e-40
GCST90002407_446	White blood cell count	9e-40
GCST90002398_346	Neutrophil count	3e-38
GCST90002398_347	Neutrophil count	9e-35
GCST90002389_423	Lymphocyte percentage of white cells	2e-33
GCST007932_49	Medication use (thyroid preparations)	2e-26
GCST90002393_233	Monocyte count	3e-25
GCST004609_179	Monocyte percentage of white cells	5e-25
GCST010571_59	Autoimmune thyroid disease	2e-24
GCST90002407_447	White blood cell count	1e-23
GCST010989_154	Body size at age 10	1e-22
GCST90002389_422	Lymphocyte percentage of white cells	2e-22
GCST004626_61	Myeloid white cell count	8e-21
GCST004610_79	White blood cell count	2e-19
GCST90002394_161	Monocyte percentage of white cells	4e-19
GCST90002394_163	Monocyte percentage of white cells	8e-19
GCST008129_11	Body mass index	1e-18
GCST90002393_235	Monocyte count	1e-18
GCST90002394_162	Monocyte percentage of white cells	4e-18

EFO canonical traits (from GWAS)

18 canonical traits:

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0005091	monocyte count
EFO:0007997	granulocyte percentage of myeloid white cells
EFO:0007989	monocyte percentage of leukocytes
EFO:0004833	neutrophil count
EFO:0004842	eosinophil count
EFO:0007987	granulocyte count
EFO:0005090	basophil count
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0005301	reading and spelling ability
EFO:0009933	Thyroid preparation use measurement
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0009819	comparative body size at age 10, self-reported
EFO:0004587	lymphocyte count
EFO:0010701	mean reticulocyte volume
EFO:0007990	neutrophil percentage of leukocytes
EFO:0007985	platelet crit

MeSH disease descriptors

2 disease descriptors:

Descriptor	Name	Tree numbers
D015470	Leukemia, Myeloid, Acute	C04.557.337.539.275; C15.378.508.539.275
D009101	Multiple Myeloma	C04.557.595.500; C14.907.454.460; C15.378.147.780.650; C15.378.463.515.460; C20.683.515.845; C20.683.780.650

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (4): CHEMBL1974 (SINGLE PROTEIN), CHEMBL3430908 (SELECTIVITY GROUP), CHEMBL4523735 (PROTEIN-PROTEIN INTERACTION), CHEMBL4630730 (PROTEIN-PROTEIN INTERACTION)

Drugs by curated mechanism of action (ChEMBL)

Drugs whose curated ChEMBL mechanism of action targets the FLT3 protein itself — single-protein targets only (drugs acting on a protein family or complex that merely includes it are excluded). Includes antibodies and oligonucleotides that bioactivity screening does not capture.

39 curated-mechanism drugs:

Drug	Modality	Max phase
FEDRATINIB	Small molecule	4
GILTERITINIB	Small molecule	4
MIDOSTAURIN	Small molecule	4
PACRITINIB	Small molecule	4
PEXIDARTINIB	Small molecule	4
QUIZARTINIB	Small molecule	4
SORAFENIB TOSYLATE	Small molecule	4
SUNITINIB	Small molecule	4
CM-082	Unknown	3
CRENOLANIB	Small molecule	3
DOVITINIB	Small molecule	3
FAMITINIB	Small molecule	3
LESTAURTINIB	Small molecule	3
LINIFANIB	Small molecule	3
RUSERONTINIB	Small molecule	3
AKN-028	Small molecule	2
AMUVATINIB	Small molecule	2
AT-9283	Small molecule	2
C-1311	Small molecule	2
CDX-301	Unknown	2
ENMD-2076	Small molecule	2
ENMD-981693	Small molecule	2
FORETINIB	Small molecule	2
NINGETINIB	Small molecule	2
SU-014813	Small molecule	2
TANDUTINIB	Small molecule	2
XL-999	Small molecule	2
ZOTIRACICLIB	Small molecule	2
4SC-203	Small molecule	1
AMG553	Unknown	1
AS-602868	Small molecule	1
AST-487	Small molecule	1
CEP-2563 DIHYDROCHLORIDE	Small molecule	1
CT-1578	Small molecule	1
FF-10101	Small molecule	1
FLYSYN	Unknown	1
IMC-EB10	Unknown	1
KW-2449	Small molecule	1
RG-1530	Small molecule	1

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 402,854 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

showing 60 of 143 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL1287853	FEDRATINIB	4	3,770
CHEMBL3301622	GILTERITINIB	4	2,542
CHEMBL608533	MIDOSTAURIN	4	7,641
CHEMBL2035187	PACRITINIB	4	3,544
CHEMBL3813873	PEXIDARTINIB	4	3,751
CHEMBL576982	QUIZARTINIB	4	4,647
CHEMBL2105709	QUIZARTINIB DIHYDROCHLORIDE	4	304
CHEMBL1336	SORAFENIB	4	87,476
CHEMBL535	SUNITINIB	4	80,232
CHEMBL3301610	ABEMACICLIB	4	7,497
CHEMBL1173655	AFATINIB	4	15,878
CHEMBL1289926	AXITINIB	4	16,510
CHEMBL288441	BOSUTINIB	4	12,869
CHEMBL3545311	BRIGATINIB	4	5,988
CHEMBL2105717	CABOZANTINIB	4	11,799
CHEMBL2403108	CERITINIB	4	9,002
CHEMBL601719	CRIZOTINIB	4	15,133
CHEMBL5416410	DASATINIB	4	674
CHEMBL1983268	ENTRECTINIB	4	3,737
CHEMBL553	ERLOTINIB	4	109,860
CHEMBL3301607	FILGOTINIB	4
CHEMBL2103830	FOSTAMATINIB	4
CHEMBL939	GEFITINIB	4
CHEMBL1873475	IBRUTINIB	4
CHEMBL941	IMATINIB	4
CHEMBL1852688	INFIGRATINIB	4
CHEMBL1834657	INFIGRATINIB PHOSPHATE	4
CHEMBL180022	NERATINIB	4
CHEMBL255863	NILOTINIB	4
CHEMBL502835	NINTEDANIB	4
CHEMBL189963	PALBOCICLIB	4
CHEMBL477772	PAZOPANIB	4
CHEMBL1171837	PONATINIB	4
CHEMBL4582651	PRALSETINIB	4
CHEMBL1946170	REGORAFENIB	4
CHEMBL1289494	TIVOZANIB	4
CHEMBL24828	VANDETANIB	4
CHEMBL2105728	CRENOLANIB	3
CHEMBL522892	DOVITINIB	3
CHEMBL603469	LESTAURTINIB	3
CHEMBL223360	LINIFANIB	3
CHEMBL428690	ALVOCIDIB	3
CHEMBL415049	BARASERTIB	3
CHEMBL31965	CANERTINIB	3
CHEMBL491473	CEDIRANIB	3
CHEMBL3137331	DEFACTINIB	3
CHEMBL3265032	ENTOSPLETINIB	3
CHEMBL300138	ENZASTAURIN	3
CHEMBL3904602	LEROCICLIB	3
CHEMBL1091644	LINSITINIB	3
CHEMBL572881	MOTESANIB	3
CHEMBL2316582	OLVEREMBATINIB	3
CHEMBL274654	ORANTINIB	3
CHEMBL50	QUERCETIN	3
CHEMBL165	RESVERATROL	3
CHEMBL91829	RUBOXISTAURIN	3
CHEMBL217092	SARACATINIB	3
CHEMBL276711	SEMAXANIB	3
CHEMBL3989926	SITRAVATINIB	3
CHEMBL4297190	SURUFATINIB	3

Clinical evidence (CIViC)

Drug × variant × indication, from 99 curated evidence items; also 25 prognostic, 10 oncogenic, 5 diagnostic, 1 functional. CIViC evidence level: A (validated) → B (clinical) → C (case study) → D (preclinical) → E (inferential).

showing 30 of 81 predictive associations by evidence level:

Variant	Therapy	Indication	Effect	Level	CIViC
FLT3 ITD	Gilteritinib	Acute Myeloid Leukemia	Sensitivity/Response	CIViC A	EID12621 +2
FLT3 ITD OR FLT3 D835 OR FLT3 I836	Midostaurin + Chemotherapy	Acute Myeloid Leukemia	Sensitivity/Response	CIViC A	EID11261
FLT3 ITD OR FLT3 D835 OR FLT3 I836	Gilteritinib	Acute Myeloid Leukemia	Sensitivity/Response	CIViC A	EID7728
FLT3 Mutation	Midostaurin	Acute Myeloid Leukemia	Sensitivity/Response	CIViC A	EID5261
FLT3 ITD	Sorafenib	Acute Myeloid Leukemia	Sensitivity/Response	CIViC B	EID1040 +2
FLT3 F691L	Pexidartinib	Acute Myeloid Leukemia	Sensitivity/Response	CIViC B	EID8674 +1
FLT3 ITD	Midostaurin	Acute Myeloid Leukemia	Sensitivity/Response	CIViC B	EID7061 +1
FLT3 Mutation	Nilotinib	Acute Myeloid Leukemia	Sensitivity/Response	CIViC B	EID5575 +1
FLT3 Amplification	Sunitinib	Colorectal Cancer	Sensitivity/Response	CIViC B	EID11667
FLT3 ITD	Lestaurtinib	Acute Myeloid Leukemia	Sensitivity/Response	CIViC B	EID297
FLT3 ITD	Hematopoietic Cell Transplantation + Sorafenib	Acute Myeloid Leukemia	Sensitivity/Response	CIViC B	EID9069
FLT3 ITD	Sorafenib + Hematopoietic Cell Transplantation	Acute Myeloid Leukemia	Sensitivity/Response	CIViC B	EID9070
FLT3 ITD	Pacritinib	Acute Myeloid Leukemia	Sensitivity/Response	CIViC B	EID9217
FLT3 Mutation	Gilteritinib	Acute Myeloid Leukemia	Sensitivity/Response	CIViC B	EID7283
FLT3 TKD MUTATION	Midostaurin	Acute Myeloid Leukemia	Sensitivity/Response	CIViC B	EID1295
FLT3 F691L	Quizartinib	Acute Myeloid Leukemia	Resistance	CIViC B	EID9718 +1
FLT3 D835	Quizartinib + Sorafenib	Acute Myeloid Leukemia	Resistance	CIViC B	EID1038
FLT3 D835	Sorafenib	Acute Myeloid Leukemia	Resistance	CIViC B	EID1039
FLT3 F691L	Pexidartinib	Acute Myeloid Leukemia	Resistance	CIViC B	EID9717
FLT3 ITD	Anthracycline Antineoplastic Antibiotic + Tretinoin	Acute Promyelocytic Leukemia	Resistance	CIViC B	EID1112
FLT3 ITD	Selumetinib	Acute Myeloid Leukemia	Resistance	CIViC B	EID1137
FLT3 ITD	Tretinoin	Acute Myeloid Leukemia	Resistance	CIViC B	EID127
FLT3 TKD MUTATION	Sorafenib	Acute Myeloid Leukemia	Resistance	CIViC B	EID248
FLT3 T227M	Sunitinib	Renal Cell Carcinoma	Adverse Response	CIViC B	EID1317
FLT3 D835	Sunitinib	Acute Myeloid Leukemia	Sensitivity/Response	CIViC C	EID4024 +2
FLT3 D835V	Sunitinib	Acute Myeloid Leukemia	Sensitivity/Response	CIViC C	EID4022 +2
FLT3 D835Y	Sorafenib	Acute Myeloid Leukemia	Sensitivity/Response	CIViC C	EID12625 +2
FLT3 D835H	Sunitinib	Acute Myeloid Leukemia	Sensitivity/Response	CIViC C	EID4027 +1
FLT3 D835Y	Gilteritinib	Acute Myeloid Leukemia	Sensitivity/Response	CIViC C	EID12620 +1
FLT3 Amplification	Regorafenib Anhydrous	Colorectal Cancer	Sensitivity/Response	CIViC C	EID7102

CIViC column: a representative evidence item (EID); +N = additional CIViC items supporting the same association.

Clinical-actionability assertions (CIViC AMP/ASCO/CAP)

Curated AMP/ASCO/CAP tier assertions — the clinical-actionability classification (Tier I highest) for this gene’s variants, distilling the CIViC evidence above into a tiered call.

5 CIViC assertions:

Molecular profile	Disease	Therapy	Type	AMP tier	Significance
FLT3 D835Y	Acute Myeloid Leukemia	Gilteritinib †	Predictive	Tier I - Level A	Sensitivity/Response
FLT3 D835	Acute Myeloid Leukemia	Gilteritinib †	Predictive	Tier I - Level A	Sensitivity/Response
FLT3 ITD	Acute Myeloid Leukemia	Gilteritinib †	Predictive	Tier I - Level A	Sensitivity/Response
FLT3 N841I	Acute Myeloid Leukemia		Oncogenic		Oncogenic
FLT3 D835Y	Acute Myeloid Leukemia		Oncogenic		Oncogenic

† an FDA-approved companion diagnostic exists for this assertion.

CIViC curated variants (20)

Named clinical variants curated in CIViC for this gene (the catalogue beneath the predictive evidence above):

D835V (missense variant), Amplification, D835Y (missense variant), Y842C, F691L, D835I, N841I (missense variant), I836, I836S, I836T, D593del, D835 (protein altering variant), Mutation (gain of function variant,transcript variant), T227M (missense variant,SNP), M737I, ITD (inframe insertion), TKD MUTATION, Overexpression, D835H (missense variant), D835H/Y (missense variant).

PharmGKB: 1 entry (CPIC guideline: no)

PharmGKB clinical annotations

1 annotations by evidence level (1 strongest → 4):

Variant	Association	Level	Drugs	Phenotypes
rs1933437	Toxicity	3	sunitinib	Leukopenia;Myelosuppression;Neutropenia;Thrombocytopenia

PharmGKB variants

1 variants:

Variant	Genes	Level	Score	#Clin annots	Drugs
rs1933437	FLT3	3	6.50	1	sunitinib

PharmGKB variant annotations

Per-publication pharmacogenomic findings for this gene (significant associations).

3 published findings:

Variant	Drug(s)	Category	Finding	PMID
rs1933437	sunitinib	Toxicity	Genotype AA is associated with increased risk of Leukopenia and Neutropenia when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AG + GG.	PMID:26244574
rs1933437	sunitinib	Toxicity	Genotypes AG + GG is associated with decreased likelihood of Leukopenia when treated with sunitinib in people with Carcinoma, Renal Cell or Gastrointestinal Stromal Tumors as compared to genotype AA.	PMID:19667267
rs1933437	sunitinib	Toxicity	Genotypes AG + GG is associated with decreased likelihood of Thrombocytopenia when treated with sunitinib in people with Carcinoma, Renal Cell or Gastrointestinal Stromal Tumors as compared to genotype AA.	PMID:20683446

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family

Most potent curated ligand interactions (68 total), top 25:

Ligand	Action	Affinity	Parameter
faldoritinib	Irreversible inhibition	10.0	pIC50
gilteritinib	Inhibition	9.52	pIC50
nefextinib	Inhibition	9.47	pIC50
denfivontinib	Inhibition	9.4	pIC50
AC710	Inhibition	9.3	pKd
Gö 6976	Inhibition	9.15	pIC50
TTT-3002	Inhibition	9.14	pIC50
crenolanib	Inhibition	9.13	pKd
compound 8i [PMID: 22765894]	Inhibition	9.1	pIC50
compound 8h [PMID: 22765894]	Inhibition	9.07	pIC50
dorsomorphin	Inhibition	9.0	pIC50
dovitinib	Inhibition	9.0	pIC50
RGB-286638	Inhibition	9.0	pIC50
ilorasertib	Inhibition	9.0	pIC50
tuspetinib	Inhibition	8.96	pIC50
compound 2c [PMID: 24900538]	Inhibition	8.68	pIC50
compound 6li [Chan et al., 2022]	Inhibition	8.6	pKd
ENMD-2076	Inhibition	8.52	pIC50
compound 5e [PMID: 28580438]	Inhibition	8.44	pKd
faronoltinib	Inhibition	8.4	pIC50
compound 34f [PMID: 37535845]	Inhibition	8.4	pIC50
linifanib	Inhibition	8.4	pIC50
URMC-099	Inhibition	8.4	pIC50
quizartinib	Inhibition	8.38	pIC50
mivavotinib	Inhibition	8.34	pIC50

Binding affinities (BindingDB)

3824 measured of 4881 human assays (4965 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
[6-cyclopropyl-3-[6-[[(3S,4S)-4-fluoropyrrolidin-3-yl]amino]-2-pyridinyl]imidazo[1,2-a]pyridin-7-yl]methanol	KD	0.007 nM	US-20230303563: MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
6-[6-(difluoromethyl)imidazo[1,2-a]pyridin-3-yl]-N-[(3S,4S)-4-fluoropyrrolidin-3-yl]pyridin-2-amine	KD	0.007 nM	US-20230303563: MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
Exemplary Synthetic Procedure #38	KD	0.008 nM	US-20230303563: MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
2-(3-(6-(((3S,4S)-4- fluoropyrrolidin-3- yl)amino)pyridin-2-yl)-7- methoxyimidazo[1,2- a]pyridin-6-yl)propan-2-ol	KD	0.009 nM	US-20230303563: MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
6-(6- (difluoromethyl)imidazo[1,2- a]pyridin-3-yl)-N-((3R,4S)-4- (trifluoromethyl)pyrrolidin-3- yl)pyridin-2-amine	KD	0.009 nM	US-20230303563: MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
6-(6- (difluoromethyl)imidazo[1,2- a]pyridin-3-yl)-N-(2,2- dimethylpyrrolidin-3- yl)pyridin-2-amine	KD	0.009 nM	US-20230303563: MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
N-(6-(6- (difluoromethyl)imidazo[1,2- a]pyridin-3-yl)pyridin-2-yl)-2- azaspiro[3.4]octan-6-amine	KD	0.01 nM	US-20230303563: MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
6-(6-(difluorometh- oxy)imidazo[1,2-a]- pyridin-3-yl)-N-((3S, 4S)-4-fluoropyrrolidin- 3-yl)pyridin-2-amine	KD	0.011 nM	US-20230303563: MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
6-(6-(1-cyclopropyl-1H- pyrazol-4-yl)imidazo- [1,2-a]pyridin-3-yl)-N- ((3S,4S)-4-fluoro- pyrrolidin-3-yl)pyridin- 2-amine	KD	0.011 nM	US-20230303563: MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
N-((3S,4S)-4-fluoro- pyrrolidin-3-yl)-6-(6-(1- methyl-1H-pyrazol-4- yl)imidazo[1,2-a]pyridin- 3-yl)pyridin-2-amine	KD	0.012 nM	US-20230303563: MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
CHEMBL4744130	IC50	0.015 nM
1-(4-(3-(6-(((3S,4S)-4- fluoropyrrolidin-3-yl)- amino)pyridin-2-yl)- imidazo[1,2-a]pyridin-6- yl)-1H-pyrazol-1-yl)-2- methylpropan-2-ol	KD	0.016 nM	US-20230303563: MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
2-(3-(6-(((3S,4S)-4- fluoropiperidin-3- yl)amino)pyridin-2-yl)-7- methoxyimidazo[1,2- a]pyridin-6-yl)propan-2-ol	KD	0.017 nM	US-20230303563: MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
N-((3S,4S)-4- fluoropyrrolidin-3-yl)-6-(7- isopropoxyimidazo[1,2- a]pyridin-3-yl)pyridin-2- amine	KD	0.018 nM	US-20230303563: MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
(R)-N-(6-(6- (difluoromethyl)imidazo[1,2- a]pyridin-3-yl)pyridin-2-yl)-5- azaspiro[2.4]heptan-7-amine	KD	0.02 nM	US-20230303563: MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
CHEMBL5440655	IC50	0.024 nM
3,5-difluoro-N-((3S,4S)-4- fluoropiperidin-3-yl)-6-(7- isopropoxyimidazo[1,2- a]pyridin-3-yl)pyridin-2- amine	KD	0.025 nM	US-20230303563: MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
N-(6-(6-(1-methyl- cyclopropyl)imidazo- [1,2-a]pyridin-3-yl)- pyridin-2-yl)-2- azaspiro[3.4]octan-6- amine	KD	0.034 nM	US-20230303563: MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
CHEMBL4519741	IC50	0.038 nM
3,5-difluoro-N-((3S,4S)-4- fluoropyrrolidin-3-yl)-6- (7- isopropoxyimidazo[1,2- a]pyridin-3-yl)pyridin-2- amine	KD	0.049 nM	US-20230303563: MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF
3-[2-(Imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide	EC50	0.05 nM
CHEMBL6191359	IC50	0.05 nM
CHEMBL6191849	IC50	0.05 nM
CHEMBL6192901	IC50	0.05 nM
CHEMBL6189235	IC50	0.05 nM
(17E)-16-ethyl-8,12,14-trimethyl- 2,11,12,14-tetrahydro-8H-3,5- ethenotripyrazolo[3,4-f:3’,4’-j:4″,3″- n][1,4]oxazacyclopentadecin-13(10H)- one	KD	0.058 nM	US-20260070924: INDAZOLE MACROCYCLES AND THEIR USE
CHEMBL6192930	IC50	0.06 nM
CHEMBL5641913	IC50	0.061 nM
CHEMBL5641673	IC50	0.061 nM
CHEMBL5639694	IC50	0.063 nM
CHEMBL5639591	IC50	0.063 nM
CHEMBL4790915	IC50	0.072 nM
CHEMBL6188781	IC50	0.08 nM
CHEMBL6189029	IC50	0.08 nM
CHEMBL6192679	IC50	0.08 nM
CHEMBL6191366	IC50	0.09 nM
CHEMBL5639373	IC50	0.102 nM
CHEMBL5593388	IC50	0.11 nM
CHEMBL5646935	IC50	0.117 nM
CHEMBL5647067	IC50	0.118 nM
CHEMBL5646820	IC50	0.119 nM
CHEMBL5639601	IC50	0.132 nM
CHEMBL6190161	IC50	0.14 nM
CHEMBL5618643	IC50	0.142 nM
CHEMBL5639222	IC50	0.147 nM
CHEMBL5639369	IC50	0.147 nM
CHEMBL4790597	IC50	0.15 nM
CHEMBL6189611	IC50	0.15 nM
CHEMBL6192249	IC50	0.16 nM
CHEMBL5640024	IC50	0.168 nM

ChEMBL bioactivities

6100 potent at pChembl≥5 of 6100 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
11.00	Kd	0.01	nM	CHEMBL5176837
11.00	Kd	0.01	nM	CHEMBL5927784
10.92	Kd	0.012	nM	CHEMBL5176837
10.82	IC50	0.015	nM	CHEMBL4744130
10.81	Kd	0.0154	nM	CHEMBL5195819
10.80	Kd	0.016	nM	CRENOLANIB
10.77	Kd	0.017	nM	CHEMBL6078253
10.68	Kd	0.021	nM	CHEMBL6002371
10.62	IC50	0.024	nM	CHEMBL5440655
10.60	Kd	0.025	nM	CHEMBL5927784
10.47	Kd	0.034	nM	CHEMBL6078253
10.42	IC50	0.038	nM	CHEMBL4519741
10.30	IC50	0.05	nM	CHEMBL6191359
10.30	IC50	0.05	nM	CHEMBL6191849
10.30	IC50	0.05	nM	CHEMBL6192901
10.30	IC50	0.05	nM	CHEMBL6189235
10.25	Kd	0.056	nM	CHEMBL6078253
10.22	IC50	0.06	nM	CRENOLANIB
10.22	IC50	0.06	nM	CHEMBL6192930
10.21	IC50	0.061	nM	CHEMBL5641913
10.21	IC50	0.061	nM	CHEMBL5641673
10.20	IC50	0.063	nM	CHEMBL5639694
10.20	IC50	0.063	nM	CHEMBL5639591
10.19	Kd	0.065	nM	CHEMBL6002371
10.14	IC50	0.072	nM	CHEMBL4790915
10.13	Kd	0.074	nM	CHEMBL6078253
10.10	IC50	0.08	nM	CHEMBL6188781
10.10	IC50	0.08	nM	CHEMBL6189029
10.10	IC50	0.08	nM	CHEMBL6192679
10.05	IC50	0.09	nM	CHEMBL6191366
10.03	Kd	0.093	nM	CHEMBL256961
10.00	IC50	0.101	nM	CHEMBL4086149
10.00	IC50	0.1	nM	CHEMBL4513768
10.00	Ki	0.1	nM	CHEMBL4864449
10.00	Ki	0.1	nM	CHEMBL4870188
10.00	IC50	0.1	nM	CHEMBL5268237
10.00	Kd	0.1	nM	CHEMBL6078253
10.00	Ki	0.1	nM	CHEMBL273187
9.99	IC50	0.102	nM	CHEMBL5639373
9.96	IC50	0.11	nM	CHEMBL5593388
9.96	Kd	0.11	nM	CHEMBL6002371
9.93	IC50	0.118	nM	CHEMBL5647067
9.93	IC50	0.117	nM	CHEMBL5646935
9.92	IC50	0.121	nM	CHEMBL5440655
9.92	IC50	0.119	nM	CHEMBL5646820
9.92	Kd	0.12	nM	CHEMBL6002371
9.91	IC50	0.123	nM	CHEMBL3612622
9.89	IC50	0.13	nM	CHEMBL4092761
9.88	IC50	0.132	nM	CHEMBL5639601
9.85	IC50	0.14	nM	CHEMBL6190161

PubChem BioAssay actives

3025 with measured affinity, of 6100 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
6-[7-methoxy-6-(1-methylpyrazol-4-yl)imidazo[1,2-a]pyridin-3-yl]-N-pyrrolidin-3-ylpyridin-2-amine	1894563: Binding affinity to FLT3-ITD-D835V mutant (unknown origin) assessed as dissociation constant	kd	<0.0001	uM
1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[3-fluoro-4-(1H-imidazo[4,5-b]pyridin-7-yloxy)phenyl]urea	1696916: Inhibition of FLT3 ITD mutant (unknown origin) expressed in mouse BaF3 cells	ic50	<0.0001	uM
2-[3-[6-[[(3S,4S)-4-fluoropiperidin-3-yl]amino]-2-pyridinyl]-7-methoxyimidazo[1,2-a]pyridin-6-yl]propan-2-ol	2205385: Binding affinity to FLT3 D835V mutant (unknown origin) expressed in Escherichia coli BL21 assessed as dissociation constant by DiscoverX KINOMEscan assay	kd	<0.0001	uM
6-(6-cyclopropyl-7-methoxyimidazo[1,2-a]pyridin-3-yl)-N-[(3S,4S)-4-fluoropyrrolidin-3-yl]pyridin-2-amine	2205370: Inhibition of NanoLuc-fused FLT3 ITD/D835Y mutant (unknown origin) transfected in HEK293 cells incubated for 1 hr by NanoBRET assay	ic50	<0.0001	uM
2-[(E)-[2-(2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino]oxy-1-piperazin-1-ylethanone;hydrochloride	1868178: Binding affinity to FLT3 ITD/F691L double mutant (unknown origin) by KINOMEscan assay	kd	<0.0001	uM
N-[(5-methyl-1H-imidazol-2-yl)methyl]-4-(8,9,10,11-tetrahydro-3H-pyrazolo[4,5-a]phenanthridin-7-yl)benzamide	2003941: Inhibition of FLT3 D835Y mutant (unknown origin)	ic50	<0.0001	uM
1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine	1562814: Inhibition of FLT3 D835Y mutant (unknown origin)	ic50	0.0001	uM
5-chloro-3-[1-(2-methyl-5-nitrophenyl)sulfonylpyrrol-3-yl]pyrazolo[1,5-a]pyrimidine	1245695: Inhibition of FLT3 (unknown origin) using biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 as substrate after 90 mins by luminescence assay	ic50	0.0001	uM
1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]urea	1696916: Inhibition of FLT3 ITD mutant (unknown origin) expressed in mouse BaF3 cells	ic50	0.0001	uM
N-[6-(4-ethylpiperazin-1-yl)-2-methylpyrimidin-4-yl]-5-pyridin-4-yl-1,3-thiazol-2-amine;hydrochloride	1581288: Inhibition of wild type FLT3 (unknown origin) expressed in HEK293T cells assessed as decrease in FLT3 phosphorylation at 0.1 to 1000 nM after 1 hr by Western blot analysis	ic50	0.0001	uM
4-[(6-ethylthieno[2,3-d]pyrimidin-4-yl)amino]-N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-1H-pyrazole-5-carboxamide	1489804: Inhibition of human FLT3 using EAIYAAPFAKKK as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition measure after 120 mins by filter binding method	ic50	0.0001	uM
N-[4-(diethylaminomethyl)phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide	1489804: Inhibition of human FLT3 using EAIYAAPFAKKK as substrate preincubated for 20 mins followed by [gamma-33P]-ATP addition measure after 120 mins by filter binding method	ic50	0.0001	uM
4-[3-[(E)-2-[3-fluoro-4-(morpholin-4-ylmethyl)phenyl]ethenyl]-1H-indazol-6-yl]pyrimidin-2-amine	2279207: Inhibition of His-tagged human recombinant FLT3 catalytic domain (564 to 958 residues) expressed in insect cells using ATP as substrate incubated for 60 mins by LanthaScreen analysis	ic50	0.0001	uM
4-[3-[(E)-2-(4-morpholin-4-ylphenyl)ethenyl]-1H-indazol-6-yl]pyridin-2-amine	2279207: Inhibition of His-tagged human recombinant FLT3 catalytic domain (564 to 958 residues) expressed in insect cells using ATP as substrate incubated for 60 mins by LanthaScreen analysis	ic50	0.0001	uM
4-[3-[(E)-2-[4-(4-methylpiperazin-1-yl)phenyl]ethenyl]-1H-indazol-6-yl]pyridin-2-amine	2279207: Inhibition of His-tagged human recombinant FLT3 catalytic domain (564 to 958 residues) expressed in insect cells using ATP as substrate incubated for 60 mins by LanthaScreen analysis	ic50	0.0001	uM
4-[3-[(E)-2-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]ethenyl]-1H-indazol-6-yl]pyridin-2-amine	2279207: Inhibition of His-tagged human recombinant FLT3 catalytic domain (564 to 958 residues) expressed in insect cells using ATP as substrate incubated for 60 mins by LanthaScreen analysis	ic50	0.0001	uM
4-[3-[(E)-2-[3-fluoro-4-(morpholin-4-ylmethyl)phenyl]ethenyl]-1H-indazol-6-yl]pyridin-2-amine	2279207: Inhibition of His-tagged human recombinant FLT3 catalytic domain (564 to 958 residues) expressed in insect cells using ATP as substrate incubated for 60 mins by LanthaScreen analysis	ic50	0.0001	uM
N-[(2S,4S,6R)-2,6-dimethyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-4-yl]-N-methylbenzamide	1691299: Inhibition of human FLT3 D835Y mutant EAIYAAPFAKKK peptide as substrate in presence of 33P-gamma ATP by hotspot kinase assay	ic50	0.0001	uM
1-[4-[3-[[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]-1,4-diazepan-1-yl]ethanone	1756404: Inhibition of FLT3 ITD mutant (unknown origin) using Glu/Tyr peptide substrate incubated for 120 mins measured after 40 mins incubation under dark by ADP-glo based luminescence assay	ki	0.0001	uM
1-[4-[4-[[4-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone	1756404: Inhibition of FLT3 ITD mutant (unknown origin) using Glu/Tyr peptide substrate incubated for 120 mins measured after 40 mins incubation under dark by ADP-glo based luminescence assay	ki	0.0001	uM
3-(6-morpholin-4-yl-1H-benzimidazol-2-yl)-N-[(3R)-pyrrolidin-3-yl]-1H-indazole-5-carboxamide	2143345: Inhibition of recombinant wild type FLT3 kinase domain (unknown origin) using peptide substrate incubated for for 30 mins by HTRF assay	ic50	0.0001	uM
(4-aminopiperidin-1-yl)-[3-(6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-indazol-5-yl]methanone	2143345: Inhibition of recombinant wild type FLT3 kinase domain (unknown origin) using peptide substrate incubated for for 30 mins by HTRF assay	ic50	0.0001	uM
N-(3-aminopropyl)-3-(6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-indazole-5-carboxamide	2143345: Inhibition of recombinant wild type FLT3 kinase domain (unknown origin) using peptide substrate incubated for for 30 mins by HTRF assay	ic50	0.0001	uM
N-[(1S,3S)-3-aminocyclopentyl]-3-(6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-indazole-5-carboxamide	2143345: Inhibition of recombinant wild type FLT3 kinase domain (unknown origin) using peptide substrate incubated for for 30 mins by HTRF assay	ic50	0.0001	uM
N-(3-aminopropyl)-3-(6-piperidin-1-yl-1H-benzimidazol-2-yl)-1H-indazole-5-carboxamide	2143345: Inhibition of recombinant wild type FLT3 kinase domain (unknown origin) using peptide substrate incubated for for 30 mins by HTRF assay	ic50	0.0001	uM
N-[(1S,3R)-3-aminocyclopentyl]-3-(6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-indazole-5-carboxamide	2143345: Inhibition of recombinant wild type FLT3 kinase domain (unknown origin) using peptide substrate incubated for for 30 mins by HTRF assay	ic50	0.0001	uM
N-[(1S,3S)-3-aminocyclopentyl]-3-(6-methoxy-1H-benzimidazol-2-yl)-1H-indazole-5-carboxamide	2143349: Inhibition of recombinant FLT3 D835Y mutant (unknown origin) using peptide substrate incubated for for 30 mins by HTRF assay	ic50	0.0001	uM
3-(6-morpholin-4-yl-1H-benzimidazol-2-yl)-N-[[(3S)-pyrrolidin-3-yl]methyl]-1H-indazole-5-carboxamide	2143345: Inhibition of recombinant wild type FLT3 kinase domain (unknown origin) using peptide substrate incubated for for 30 mins by HTRF assay	ic50	0.0001	uM
N-[3-(dimethylamino)propyl]-3-(6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-indazole-5-carboxamide	2143345: Inhibition of recombinant wild type FLT3 kinase domain (unknown origin) using peptide substrate incubated for for 30 mins by HTRF assay	ic50	0.0001	uM
3-(6-morpholin-4-yl-1H-benzimidazol-2-yl)-N-[[(3R)-pyrrolidin-3-yl]methyl]-1H-indazole-5-carboxamide	2143345: Inhibition of recombinant wild type FLT3 kinase domain (unknown origin) using peptide substrate incubated for for 30 mins by HTRF assay	ic50	0.0001	uM
N-(4-aminocyclohexyl)-3-(6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-indazole-5-carboxamide	2143345: Inhibition of recombinant wild type FLT3 kinase domain (unknown origin) using peptide substrate incubated for for 30 mins by HTRF assay	ic50	0.0001	uM
piperazin-1-yl-[4-[(E)-2-(6-pyridin-4-yl-1H-indazol-3-yl)ethenyl]phenyl]methanone	2279207: Inhibition of His-tagged human recombinant FLT3 catalytic domain (564 to 958 residues) expressed in insect cells using ATP as substrate incubated for 60 mins by LanthaScreen analysis	ic50	0.0001	uM
[4-[(E)-2-[6-(2-amino-4-pyridinyl)-1H-indazol-3-yl]ethenyl]phenyl]-morpholin-4-ylmethanone	2279207: Inhibition of His-tagged human recombinant FLT3 catalytic domain (564 to 958 residues) expressed in insect cells using ATP as substrate incubated for 60 mins by LanthaScreen analysis	ic50	0.0001	uM
3-N-[4-(4-morpholin-4-ylcyclohexyl)phenyl]-1-pyridin-2-yl-1,2,4-triazole-3,5-diamine	649408: Inhibition of human recombinant FLT3 by radiometric assay	ki	0.0002	uM
N-[(E)-(5-cyanopyrazolo[1,5-a]pyrimidin-3-yl)methylideneamino]-N,2-dimethyl-5-nitrobenzenesulfonamide	1245695: Inhibition of FLT3 (unknown origin) using biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 as substrate after 90 mins by luminescence assay	ic50	0.0002	uM
N-[2-(5-chloropyrazolo[1,5-a]pyrimidin-3-yl)ethyl]-2-methyl-5-nitrobenzenesulfonamide	1245695: Inhibition of FLT3 (unknown origin) using biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 as substrate after 90 mins by luminescence assay	ic50	0.0002	uM
N-[2-(5-chloropyrazolo[1,5-a]pyrimidin-3-yl)ethyl]-5-cyano-N,2-dimethylbenzenesulfonamide	1245695: Inhibition of FLT3 (unknown origin) using biotin-Glu-Gly-Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 as substrate after 90 mins by luminescence assay	ic50	0.0002	uM
4-[3-[(E)-2-[4-(morpholin-4-ylmethyl)phenyl]ethenyl]-1H-indazol-6-yl]pyridin-2-amine	2279207: Inhibition of His-tagged human recombinant FLT3 catalytic domain (564 to 958 residues) expressed in insect cells using ATP as substrate incubated for 60 mins by LanthaScreen analysis	ic50	0.0002	uM
4-[(2-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)amino]-N-(4-piperazin-1-ylphenyl)-1H-pyrazole-5-carboxamide	1360758: Inhibition of human FLT3 by Hotspot assay	ic50	0.0002	uM
2-[4-(4-acetylpiperazin-1-yl)anilino]-4-(1H-indazol-3-yl)pyrimidine-5-carbonitrile	1756404: Inhibition of FLT3 ITD mutant (unknown origin) using Glu/Tyr peptide substrate incubated for 120 mins measured after 40 mins incubation under dark by ADP-glo based luminescence assay	ki	0.0002	uM
2-[(E)-[2-(2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino]oxy-N-[(3S)-pyrrolidin-3-yl]acetamide;hydrochloride	1868174: Inhibition of human recombinant His-tagged FLT3/D835Y mutant expressed in baculovirus expression system incubated for 30 mins in presence of ATP by HTRF analysis	ic50	0.0002	uM
2-[(E)-[2-(5-chloro-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino]oxy-1-piperazin-1-ylethanone;hydrochloride	1868174: Inhibition of human recombinant His-tagged FLT3/D835Y mutant expressed in baculovirus expression system incubated for 30 mins in presence of ATP by HTRF analysis	ic50	0.0002	uM
2-[(E)-[2-(2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino]oxy-N-[(3R)-pyrrolidin-3-yl]acetamide;hydrochloride	1868174: Inhibition of human recombinant His-tagged FLT3/D835Y mutant expressed in baculovirus expression system incubated for 30 mins in presence of ATP by HTRF analysis	ic50	0.0002	uM
2-[(E)-[2-(5-fluoro-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino]oxy-1-piperazin-1-ylethanone;hydrochloride	1868174: Inhibition of human recombinant His-tagged FLT3/D835Y mutant expressed in baculovirus expression system incubated for 30 mins in presence of ATP by HTRF analysis	ic50	0.0002	uM
2-[(E)-[2-(5-bromo-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino]oxy-1-piperazin-1-ylethanone;hydrochloride	1868174: Inhibition of human recombinant His-tagged FLT3/D835Y mutant expressed in baculovirus expression system incubated for 30 mins in presence of ATP by HTRF analysis	ic50	0.0002	uM
N-[(1S,3S)-3-aminocyclopentyl]-3-[6-(furan-3-yl)-1H-benzimidazol-2-yl]-1H-indazole-5-carboxamide	2143349: Inhibition of recombinant FLT3 D835Y mutant (unknown origin) using peptide substrate incubated for for 30 mins by HTRF assay	ic50	0.0002	uM
2-[7-methoxy-3-[6-[[(3R)-piperidin-3-yl]amino]-2-pyridinyl]imidazo[1,2-a]pyridin-6-yl]propan-2-ol	2205383: Binding affinity to FLT3 (unknown origin) expressed in Escherichia coli BL21 assessed as dissociation constant by DiscoverX KINOMEscan assay	kd	0.0002	uM
3-(6-morpholin-4-yl-1H-benzimidazol-2-yl)-N-(piperidin-3-ylmethyl)-1H-indazole-5-carboxamide	2143345: Inhibition of recombinant wild type FLT3 kinase domain (unknown origin) using peptide substrate incubated for for 30 mins by HTRF assay	ic50	0.0002	uM
N-(3-aminopropyl)-3-(6-pyrrolidin-1-yl-1H-benzimidazol-2-yl)-1H-indazole-5-carboxamide	2143345: Inhibition of recombinant wild type FLT3 kinase domain (unknown origin) using peptide substrate incubated for for 30 mins by HTRF assay	ic50	0.0002	uM
N-(3-amino-2-methylpropyl)-3-(6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-indazole-5-carboxamide	2143345: Inhibition of recombinant wild type FLT3 kinase domain (unknown origin) using peptide substrate incubated for for 30 mins by HTRF assay	ic50	0.0002	uM

CTD chemical–gene interactions

58 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Sorafenib	increases response to substance, decreases reaction, increases phosphorylation, decreases activity, decreases phosphorylation	5
ponatinib	decreases activity, decreases reaction, increases phosphorylation, decreases phosphorylation	4
Arsenic Trioxide	increases expression, affects binding, increases reaction, decreases phosphorylation, increases degradation (+1 more)	3
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	3
sodium arsenite	increases expression, increases phosphorylation	2
Semaxinib	decreases activity	2
Tretinoin	affects cotreatment, decreases expression, increases reaction, increases response to substance	2
2-hydroxy-1-(2-((9-(4-methylcyclohexyl)-9H-pyrido(4’,3’-4,5)pyrrolo(2,3-d)pyrimidin-2-yl)amino)-7,8-dihydro-1,6-naphthyridin-6(5H)-yl)ethanone	decreases phosphorylation	1
pexidartinib	decreases activity	1
RGFP966	affects reaction, decreases expression, decreases phosphorylation	1
bisphenol F	affects cotreatment, increases methylation	1
S63845	decreases expression, increases reaction	1
parthenolide	decreases expression, increases reaction	1
fulvic acid	affects cotreatment, decreases reaction, increases expression	1
bisphenol A	increases expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
terbufos	increases methylation	1
benzo(e)pyrene	increases methylation	1
celastrol	decreases expression	1
bafilomycin A	increases expression, increases degradation, decreases reaction	1
midostaurin	decreases response to substance, decreases activity	1
romidepsin	decreases phosphorylation, increases reaction	1
gedunin	decreases expression	1
tanespimycin	decreases expression	1
SU 5614	decreases activity	1
D-65476	affects cotreatment, decreases expression, increases reaction	1
THRX 165724	decreases phosphorylation	1
NSC 23766	affects response to substance	1
palbociclib	affects response to substance, decreases expression, decreases phosphorylation	1
5-((5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-N-(2-hydroxy-3-morpholin-4-ylpropyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide	decreases phosphorylation	1

ChEMBL screening assays

3132 unique, capped per target: 3096 binding, 24 functional, 8 admet, 4 toxicity

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1003890	Binding	Inhibition of Flt3	Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities. — *J Med Chem*
CHEMBL1963779	Functional	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: FLT3	PubChem BioAssay data set
CHEMBL3826089	ADMET	Inhibition of FLT3 (unknown origin)	Discovery of a potent and highly selective transforming growth factor β receptor-associated kinase 1 (TAK1) inhibitor by structure based drug design (SBDD). — *Bioorg Med Chem*

Cellosaurus cell lines

194 cell lines: 148 cancer cell line, 39 factor-dependent cell line, 4 embryonic stem cell, 2 spontaneously immortalized cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_0064	MV4-11	Cancer cell line	Male
CVCL_0138	ACH-2	Cancer cell line	Female
CVCL_0207	CCRF-CEM	Cancer cell line	Female
CVCL_0614	Kasumi-6	Cancer cell line	Male
CVCL_0R18	CEM-TART clone 1A2	Cancer cell line	Female
CVCL_0U11	CEM/MX1	Cancer cell line	Female
CVCL_1150	CTV-1	Cancer cell line	Male
CVCL_1B35	CEM/VM-1	Cancer cell line	Female
CVCL_1E04	Rev-CEM	Cancer cell line	Female
CVCL_1G53	CEM-GFP	Cancer cell line	Female

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 300 trials:

NCT	Phase	Status	Title
NCT00199147	Phase 4	UNKNOWN	Efficacy of G-CSF-Priming in Elderly AML Patients
NCT00304447	Phase 4	COMPLETED	Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia
NCT00464217	Phase 4	COMPLETED	Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years
NCT00487448	Phase 4	COMPLETED	SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia
NCT00488709	Phase 4	COMPLETED	Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00686543	Phase 4	COMPLETED	Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115)
NCT01041040	Phase 4	COMPLETED	LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)
NCT01198054	Phase 4	TERMINATED	LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)
NCT01200355	Phase 4	COMPLETED	Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome
NCT01347996	Phase 4	COMPLETED	Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia
NCT01587430	Phase 4	UNKNOWN	3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia
NCT01819792	Phase 4	COMPLETED	Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia
NCT02024308	Phase 4	UNKNOWN	AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy
NCT02027064	Phase 4	UNKNOWN	Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT
NCT02277847	Phase 4	UNKNOWN	Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia
NCT02386800	Phase 4	ACTIVE_NOT_RECRUITING	CINC424A2X01B Rollover Protocol
NCT02926586	Phase 4	COMPLETED	Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML
NCT02933333	Phase 4	UNKNOWN	G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
NCT03026842	Phase 4	UNKNOWN	Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)
NCT03150134	Phase 4	UNKNOWN	Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients
NCT05144243	Phase 4	ACTIVE_NOT_RECRUITING	Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China
NCT06370000	Phase 4	RECRUITING	Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality
NCT06571825	Phase 4	RECRUITING	RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR
NCT07016165	Phase 4	RECRUITING	Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies
NCT07044687	Phase 4	RECRUITING	Study to Assess Adverse Events and Change in Disease Activity of Oral Venetoclax in Combination With Subcutaneous (SC) or Intravenous (IV) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Standard Induction Therapy in India
NCT07486713	Phase 4	RECRUITING	Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
NCT07561892	Phase 4	RECRUITING	Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).
NCT07773909	Phase 4	COMPLETED	Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy
NCT00000589	Phase 3	COMPLETED	Trial to Reduce Alloimmunization to Platelets (TRAP)
NCT00044486	Phase 3	COMPLETED	Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)
NCT00093990	Phase 3	COMPLETED	Tipifarnib Versus Best Supportive Care in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)
NCT00125606	Phase 3	TERMINATED	Phase 3 Trial for AML Patients in CR2 Comparing 8Gy TBI /Fludarabine to Conditioning With TBI 12Gy/Cyclophosphamide
NCT00136084	Phase 3	COMPLETED	Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia
NCT00146120	Phase 3	COMPLETED	Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result
NCT00150878	Phase 3	TERMINATED	Standard vs. Reduced-Intensity Conditioning in Patients With Acute Myeloid Leukemia in First Remission
NCT00151255	Phase 3	COMPLETED	All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00152139	Phase 3	COMPLETED	Stem Cell Transplantation for Patients With Hematologic Malignancies
NCT00152594	Phase 3	TERMINATED	Voriconazole or Placebo in the Prophylaxis of Lung Infiltrates in Patients Undergoing Induction Chemotherapy for Acute Myelogenous Leukemia
NCT00186966	Phase 3	COMPLETED	Treatment of Children and Adolescents With Refractory or Relapsed Acute Myeloid Leukemia
NCT00226512	Phase 3	WITHDRAWN	To Determine the Role of Adding Campath-1H or ATG Given In-vivo in Addition to Fludarabine and Low Dose Busulfex on Outcome in Patients Treated With Reduced Intensity Conditioning
NCT00260832	Phase 3	COMPLETED	Trial of Decitabine in Patients With Acute Myeloid Leukemia
NCT00266136	Phase 3	COMPLETED	Biology and Treatment Strategy of AML in Its Subgroups: Multicenter Randomized Trial by the German Acute Myeloid Leukemia Cooperative Group (AMLCG)
NCT00317642	Phase 3	COMPLETED	A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)
NCT00322101	Phase 3	COMPLETED	Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
NCT00363025	Phase 3	TERMINATED	A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia.
NCT00406393	Phase 3	COMPLETED	Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
NCT00412360	Phase 3	COMPLETED	Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)
NCT00428558	Phase 3	COMPLETED	Timed-Sequential Induction in CBF-AML
NCT00469144	Phase 3	COMPLETED	IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
NCT00474006	Phase 3	COMPLETED	High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML
NCT00476541	Phase 3	COMPLETED	NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia
NCT00480064	Phase 3	COMPLETED	Lomustine and Intermediate Dose Cytarabine in Older Patients With AML
NCT00495287	Phase 3	COMPLETED	A Remission Induction Therapy and Risk-oriented Postremission Strategy for Adult Acute Myelogenous Leukemia (AML)
NCT00513305	Phase 3	TERMINATED	Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia
NCT00568633	Phase 3	TERMINATED	Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
NCT00589082	Phase 3	COMPLETED	DaunoXome + Ara-C vs Daunorubicin + Ara-C in Elderly AML
NCT00590837	Phase 3	COMPLETED	Adding Lomustine to Chemotherapy in Older Patients With Acute Myelogenous Leukemia (AML), and Allogeneic Transplantation for Patients From 60 to 65 Years Old
NCT00606723	Phase 3	COMPLETED	Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML
NCT00656448	Phase 3	COMPLETED	A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
NCT00678275	Phase 3	COMPLETED	Chronic Graft-versus-host Disease (cGvHD) Prophylaxis With or Without ATG Prior to Stem Cell Transplantation (SCT) From HLA-identical Siblings in Patients With Acute Leukemia

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for FLT3 across ~30M SureChEMBL compounds — explore on Sugi Predict.